var docs;if (!docs) docs =[]; docs["30"]={"3000":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Retinoic Acid Derivatives): St. John's wort should not be taken by patients who require reliable hormonal contraception during treatment with certain systemic retinoic acid derivatives (e.g., acitretin, isotretinoin). See manufacturer prescribing information for specific contraception guidelines.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Contraceptive failure seems possible. Consider using a product other than St John's wort. If St John's wort must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection. Patients should be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of many hormonal contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> A report describes several cases of breakthrough bleeding that occurred in patients receiving concomitant oral contraceptives and St John's wort.<sup>1</sup> The half-life of ethinyl estradiol (0.035 mg as part of a combination containing norethindrone 1 mg) was decreased approximately 50% in 12 normal premenopausal women during concomitant administration of St John's wort (300 mg three times daily for 2 cycles of oral contraceptive administration).<sup>2</sup> The incidence of breakthrough bleeding increased 3.5-fold during St John's wort administration. Another study demonstrated no significant pharmacokinetic effect of St John' wort (300 mg extract given 2 to 3 times daily) on serum estradiol or progesterone concentrations (0.02 mg ethinyl estradiol; 0.15 mg desogestrel daily) for one cycle of oral contraceptive administration.<sup>3</sup> No changes in follicle maturation occurred; however, intracyclic bleeding was increased in the St John's wort-treated group. It is presumed that such effects are due to decreased in circulating hormones in response to induction of CYP enzymes by St John's wort. At least one case of unexpected pregnancy in a patient taking an oral contraceptive and St John's wort has been published.<sup>4</sup> Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yue QY, Bergquist C, and Gerden B, “Safety of St John’s Wort,” <i>Lancet</i>, 2000, 355(9203):576-7 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10683030\">[PubMed 10683030]</a></p>\n<p>2. Hall SD, Wang Z, Huang SM, et al, “The Interaction Between St John's Wort and an Oral Contraceptive,” <i>Clin Pharmacol Ther</i>, 2003, 74(6):525-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14663455\">[PubMed 14663455]</a></p>\n<p>3. Pfrunder A, Schiesser M, Gerber S, et al, “Interaction of St John's Wort With Low-Dose Oral Contraceptive Therapy: A Randomized Controlled Trial,” <i>Br J Clin Pharmacol</i>, 2003, 56(6):683-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616430\">[PubMed 14616430]</a></p>\n<p>4. Schwarz UI, Buschel B, and Kirch W, “Unwanted Pregnancy on Self-Medication With St John's Wort Despite Hormonal Contraception,” <i>Br J Clin Pharmacol</i>, 2003, 55(1):112-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12534648\">[PubMed 12534648]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3001":"<p><b>Title</b> Progestins (Contraceptive) / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Retinoic Acid Derivatives): St. John's wort should not be taken by patients who require reliable hormonal contraception during treatment with certain systemic retinoic acid derivatives (e.g., acitretin, isotretinoin). See manufacturer prescribing information for specific contraception guidelines.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a product other than St John's wort. If St John's wort must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Contraceptive failure is possible. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> A report describes several cases of breakthrough bleeding that occurred in patients receiving concomitant oral contraceptives and St John's wort.<sup>2</sup> It is presumed that such effects are due to decreased in circulating hormones. The mechanism is unknown. It may be related to enhanced CYP3A4 isoenzyme activity induced by St John's wort, and the subsequent reduction in hormone absorption, and/or increased first-pass effect. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Yue QY, Bergquist C, and Gerden B, “Safety of St John’s Wort,” <i>Lancet</i>, 2000, 355(9203):576-7 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1068303\">[PubMed 1068303]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3002":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Tetracyclines may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Concerns generated by anecdotal reports have been refuted by more rigorous scientific and clinical data. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline*, Lymecycline, Minocycline*, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Anecdotal data indicate the possibility that tetracycline antibiotics might diminish the efficacy of hormonal contraceptives. These are almost exclusively related to estrogen-containing products.<sup>1,2,3,4,5</sup> A longitudinal, uncontrolled study showed that the incidence of pregnancy in antibiotic/oral contraceptive-receiving patients (n=356) was not statistically different from the control group [no antibiotic] (n=263).<sup>6</sup> Two small studies failed to show any pharmacokinetic effects of tetracycline or doxycycline on ethinyl estradiol or norethindrone.<sup>7,8</sup> A paucity of epidemiologic data suggests that the incidence of pregnancy that occurs with concomitant antibiotic and hormonal contraception is no greater than the incidence during the use of hormonal contraception alone without concomitant antibiotics.<sup>9,10,11</sup> A thorough review of this topic was conducted by Archer et al.<sup>12</sup> They concluded that “available scientific and pharmacokinetic data do not support the hypothesis that antibiotics (with the exception of rifampin) lower the contraceptive efficacy of oral contraceptives.” A year 2000 Practice Bulletin of the American College of Obstetrics and Gynecology recommends the use of nonhormonal contraceptives only with the concomitant use of rifampin or griseofulvin.<sup>13</sup> A proposed (yet otherwise unproven) mechanism for this potential interaction is based on the antibiotic's ability to reduce gut bacteria which are important for hydrolysis of conjugated estrogen, which subsequently permits the reabsorption of the estrogen (ie, enterohepatic circulation is interrupted, resulting in lower serum concentrations of the estrogen). No supporting evidence is available.<br><br>Of note, ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations. It is also not clear to what extent efficacy of vaginal ring products is dependent on local versus systemic effects. Therefore, caution with coadministration of interacting drugs is warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacon JF and Shenfield GM, “Pregnancy Attributable to Interaction Between Tetracycline and Oral Contraceptives,” <i>Br Med J</i>, 1980, 1:293. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7357347\">[PubMed 7357347]</a></p>\n<p>2. Back DJ, Breckenridge AM, Crawford FE, et al, “Interindividual Variation and Drug Interactions With Hormonal Steroids,” <i>Drugs</i>, 1981, 21:46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7009137\">[PubMed 7009137]</a></p>\n<p>3. Back DJ, Grimmer FM, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25:527-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3408633\">[PubMed 3408633]</a></p>\n<p>4. London BM and Lookingbill DP, “Frequency of Pregnancy in Acne Patients Taking Oral Antibiotics and Oral Contraceptives,” <i>Arch Dermatol</i>, 1994, 130:392-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8129425\">[PubMed 8129425]</a></p>\n<p>5. Hughes BR and Cunliffe WJ, “Interactions Between the Oral Contraceptive Pill and Antibiotics,” <i>Br J Dermatol</i>, 1990, 122:717. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2141276\">[PubMed 2141276]</a></p>\n<p>6. Helms SE, Bredle DL, Zajic J, et al, “Oral Contraceptive Failure Rates and Oral Antibiotics,” <i>J Am Acad Dermatol</i>, 1997, 36:705-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9146531\">[PubMed 9146531]</a></p>\n<p>7. Murphy AA, Zacur HA, Charache P, et al, “The Effect of Tetracycline on Levels of Oral Contraceptives,” <i>Am J Obst Gynecol</i>, 1991, 164:28-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1986620\">[PubMed 1986620]</a></p>\n<p>8. Neely JL, Abate M, Swinker M, et al, “The Effect of Doxycycline on Serum Levels of Ethinyl Estradiol, Norethindrone, and Endogenous Progesterone,” <i>Obstet Gynecol</i>, 1991, 77:416-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1992409\">[PubMed 1992409]</a></p>\n<p>9. Sparrow MJ, “Pill Method Failures,” <i>N Z Med J</i>, 1987, 100:102-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3470667\">[PubMed 3470667]</a></p>\n<p>10. Back DJ, Grimmer SF, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25:527-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3408633\">[PubMed 3408633]</a></p>\n<p>11. Helms SE, Bredle DL, Zajic J, et al, “Oral Contraceptive Failure Rates and Oral Antibiotics,” <i>J Am Acad Dermatol</i>, 1997, 36:705-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9146531\">[PubMed 9146531]</a></p>\n<p>12. Archer JS and Archer DF, “Oral Contraceptive Efficacy and Antibiotic Interaction: A Myth Debunked,” <i>J Am Acad Dermatol</i>, 2002, 46:917-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12063491\">[PubMed 12063491]</a></p>\n<p>13. ACOG Practice Bulletin, The Use of Hormonal Contraception in Women With Coexisting Medical Conditions, July, 2000, The American College of Obstetricians and Gynecologists, Washington DC.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3003":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Topiramate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Topiramate may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Contraceptive failure with this combination is possible, particularly at higher topiramate doses (i.e., 200mg/day or greater). The risk for a significant interaction with lower topiramate doses appears to be lower but is uncertain. Some authors have advised the use of oral contraceptives that contain at least 50 mcg of ethinyl estradiol to ensure adequate concentrations of the hormone, but the efficacy of this approach is not proven. Patients should be advised to report any changes in bleeding patterns but that loss of contraceptive effectiveness can occur without any change in bleeding pattern. A non-hormonal form of contraception should be considered if a greater certainty of pregnancy prevention is desired.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Ethinyl estradiol (from combination oral contraceptive including norethindrone) AUC was decreased by 18%, 21%, and 30% in 12 patients receiving concomitant topiramate 200mg/day, 400mg/day, and 800mg/day, respectively.<sup>1</sup> Another study demonstrated nonsignificant changes in ethinyl estradiol AUC (+5% to -12%) following one month of concomitant therapy with lower doses of topiramate (50-200 mg/day).<sup>2</sup> Concentrations of the progestin component (norethindrone) were not significantly altered in either clinical study.<sup>1,2</sup> There are no known reports of contraceptive failure with this combination, but topiramate prescribing information cautions that there may be a risk for decreased contraceptive effectiveness and increased breakthrough bleeding with the combination.<sup>3</sup> Also, the authors of one review have recommended the use of oral contraceptives that contain at least 50mcg of ethinyl estradiol to ensure adequate concentrations of the hormone (for all enzyme-inducing anticonvulsant medications, including topiramate).<sup>4</sup> Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.<br><br>The mechanism of this interaction appears to be dose-dependent induction of CYP3A4-mediated metabolism of ethinyl estradiol by topiramate. A study in human hepatocytes has demonstrated dose-dependent induction of CYP3A4 activity, protein, and mRNA by topiramate, an effect that was associated with activated by activation of the Pregnane X Receptor (PXR).<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rosenfeld WE, Doose DR, Walker SA, et al, “Effect of Topiramate on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Patients With Epilepsy,” <i>Epilepsia</i>, 1997, 38(3):317-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9070594\">[PubMed 9070594]</a></p>\n<p>2. Doose DR, Wang SS, Padmanabhan M, et al, “Effect of Topiramate or Carbamazepine on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Healthy Obese and Nonobese Female Subjects,” <i>Epilepsia</i>, 2003, 44(4):540-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12681003\">[PubMed 12681003]</a></p>\n<p>3. Prescribing information. Topamax (topiramate). Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., December 2008.</p>\n<p>4. Harden CL, Leppik I, “Optimizing Therapy of Seizures in Women Who Use Oral Contraceptives,” <i>Neurology</i>, 2006, 67:S56-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17190925\">[PubMed 17190925]</a></p>\n<p>5. Nallani SC, Glauser TA, Hariparsad N, et al, “Dose-Dependent Induction of Cytochrome P450 (CYP) 3A4 and Activation of Pregnane X Receptor by Topiramate,” <i>Epilepsia</i>, 2003, 44:1521-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14636322\">[PubMed 14636322]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3004":"<p><b>Title</b> Vitamin K Antagonists / Estrogen Derivatives (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Estrogen Derivatives (Contraceptive) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> It is generally accepted that concomitant therapy with estrogen-containing contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders. If a coumarin derivative must be used in a patient desiring effective birth control, methods other than combination contraceptives should be used (i.e., nonhormonal). If concomitant therapy is used, diligently monitor for changes in coagulation status when the contraceptive is added or discontinued, or either agent is changed in dose.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol*</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of single doses of phenprocoumon was increased 25% in 7 women receiving oral contraceptives compared to matched controls receiving no oral contraceptives.<sup>1</sup> The anticoagulant effects of single doses of dicumarol were decreased in 3 of 4 normal subjects after a 20-day course of oral contraceptive (containing norethynodrel and mestranol).<sup>2</sup> In contrast, the dosage requirements of acenocoumarol was decreased approximately 20% in 12 patients taking estrogen/progestin combination oral contraceptives over the course of approximately 2 years.<sup>3</sup> Especially in light of the conflicting effects between various anticoagulants, the mechanism of potential interactions is unclear. Serum concentrations/activity of some clotting factors appears to be increased by estrogens and/or progestins.<sup>4</sup> In the case of phenprocoumon, metabolism (glucuronidation) of the anticoagulant might be increased.<sup>5</sup> The ability of estrogen-only or progestin-only contraceptives to cause similar problems is unknown and, therefore, should be managed in the same way as combination products.<br><br>Of note, ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations. Therefore, caution with coadministration of interacting drugs is warranted with these routes of estrogen administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Monig H, Baese C, and Heidemann HT, “Effect of Oral Contraceptive Steroids on the Pharmacokinetics of Phenprocoumon,” <i>Br J Clin Pharmacol</i>, 1990, 30:115-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2390422\">[PubMed 2390422]</a></p>\n<p>2. Schrogie JJ, Solomon HM, and Zieve PD, “Effect of Oral Contraceptives on Vitamin K-Dependent Clotting Activity,” <i>Clin Pharmacol Ther</i>, 1967, 8:670. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4167917\">[PubMed 4167917]</a></p>\n<p>3. de Teresa E, Vera A, Ortigosa J, et al, “Interaction Between Anticoagulants and Contraceptives: An Unsuspected Finding,” <i>Br Med J</i>, 1979, 2:1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=519402\">[PubMed 519402]</a></p>\n<p>4. Robinson GE, Burren T, Mackie IJ, et al, “Changes in Haemostasis After Stropping the Combined Contraceptive Pill: Implications for Major Surgery,” <i>BMJ</i>, 1991, 302:269-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1998792\">[PubMed 1998792]</a></p>\n<p>5. Poller L, Thomson JM, Tabiowo A, et al, “Progesterone Oral Contraception and Blood Coagulation,” <i>Br Med J</i>, 1969, 1:554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4179339\">[PubMed 4179339]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3005":"<p><b>Title</b> Vitamin K Antagonists / Progestins (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Progestins (Contraceptive) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> It is generally accepted that concomitant therapy with hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders. If a coumarin derivative must be used in a patient desiring effective birth control, methods other than hormonal contraceptives should be used. If concomitant therapy is used, diligently monitor for changes in coagulation status when the contraceptive is added or discontinued, or either agent is changed in dose.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The clearance of single doses of phenprocoumon was increased 25% in 7 women receiving oral contraceptives compared to matched controls receiving no oral contraceptives.<sup>1</sup> The anticoagulant effects of single doses of dicumarol were decreased in 3 of 4 normal subjects after a 20-day course of oral contraceptive (containing norethynodrel and mestranol).<sup>2</sup> In contrast, the dosage requirements of acenocoumarol was decreased approximately 20% in 12 patients taking estrogen/progestin combination oral contraceptives over the course of approximately 2 years.<sup>3</sup> A single case of increased INR (from 2.1 to 8.1) occurred in a warfarin-stable patient within 3 days of initiating levonorgestrel for emergency contraception.<sup>4</sup> Especially in light of the conflicting effects between various anticoagulants, the mechanism of potential interactions is unclear. Serum concentrations/activity of some clotting factors appears to be increased by estrogens and/or progestins.<sup>5</sup> In the case of phenprocoumon, metabolism (glucuronidation) of the anticoagulant might be increased.<sup>6</sup> The ability of estrogen-only or progestin-only contraceptives to cause similar problems is unknown and, therefore, should be managed in the same way as combination products. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Monig H, Baese C, and Heidemann HT, “Effect of Oral Contraceptive Steroids on the Pharmacokinetics of Phenprocoumon,” <i>Br J Clin Pharmacol</i>, 1990, 30:115-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2390422\">[PubMed 2390422]</a></p>\n<p>2. Schrogie JJ, Solomon HM, and Zieve PD, “Effect of Oral Contraceptives on Vitamin K-Dependent Clotting Activity,” <i>Clin Pharmacol Ther</i>, 1967, 8:670. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4167917\">[PubMed 4167917]</a></p>\n<p>3. de Teresa E, Vera A, Ortigosa J, et al, “Interaction Between Anticoagulants and Contraceptives: An Unsuspected Finding,” <i>Br Med J</i>, 1979, 2:1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=519402\">[PubMed 519402]</a></p>\n<p>4. Ellison J, Thomson AJ, Greer IA, et al, “Apparent Interaction Between Warfarin and Levonorgestrel Used for Emergency Contraception,” <i>BMJ</i>, 2000, 321(7273):1382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11099283\">[PubMed 11099283]</a></p>\n<p>5. Robinson GE, Burren T, Mackie IJ, et al, “Changes in Haemostasis After Stopping the Combined Contraceptive Pill: Implications for Major Surgery,” <i>Br Med J</i>, 1991, 302:269-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1998792\">[PubMed 1998792]</a></p>\n<p>6. Poller L, Thomson JM, Tabiowo A, et al, “Progesterone Oral Contraception and Blood Coagulation,” <i>Br Med J</i>, 1969, 1:554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4179339\">[PubMed 4179339]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3010":"<p><b>Title</b> Succinylcholine / Cyclophosphamide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cyclophosphamide may increase the serum concentration of Succinylcholine. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days. If succinylcholine is administered under these circumstances, consider reduced succinylcholine doses (a serum pseudocholinesterase assay may help inform this reduction) and monitor closely for increased neuromuscular blocking effects.</p> \n<p><b>Discussion</b> Prolonged apnea and other symptoms of respiratory insufficiency have been reported to occur in patients receiving succinylcholine following cyclophosphamide administration.<sup>1,2,3,4</sup> Cyclophosphamide can cause prolonged inhibition of pseudocholinesterase, a serum enzyme that metabolizes succinylcholine, and U.S. prescribing information for cyclophosphamide cautions about the potential for potentiation of succinylcholine effects up to 10 days after cyclophosphamide administration.<sup>5</sup> Based on one published case report, this interaction may be managed in some patients with succinylcholine dose reduction and close monitoring,<sup>6</sup> although general recommendations are not currently available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Walker IR, Zapf PW, and Mackay IR, “Cyclophosphamide, Cholinesterase, and Anaesthesia,” <i>Aust NZ J Med</i>, 1972, 3:247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4508246\">[PubMed 4508246]</a></p>\n<p>2. Zsigmond EK and Robins G, “The Effect of a Series of Anti-Cancer Drugs on Plasma Cholinesterase Activity,” <i>Can Anaesth Soc J</i>, 1972, 19:75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4257896\">[PubMed 4257896]</a></p>\n<p>3. Mone JG and Mathie WE, “Qualitative and Quantitative Effects of Pseudocholinesterase Activity,” <i>Anaesthesia</i>, 1967, 22:55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4959505\">[PubMed 4959505]</a></p>\n<p>4. Norris JC, “Prolonged Succinylcholine Apnoea Resulting From Acquired Deficiency of Plasma Cholinesterase,” <i>Anaesthesia</i>, 2003, 58(11):1137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616624\">[PubMed 14616624]</a></p>\n<p>5. Prescribing information. Cytoxan (cyclophosphamide). Deerfield, IL: Baxter Healthcare Corporation, April 2012.</p>\n<p>6. Dillman JB, “Safe Use of Succinylcholine During Repeated Anesthetics in a Patient Treated With Cyclophosphamide,” <i>Anesth Analg</i>, 1987, 66(4):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3565800\">[PubMed 3565800]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3012":"<p><b>Title</b> CycloSERINE / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitorclosely for toxic CNS effects (eg, drowsiness, dizziness) during concomitant treatment with cycloserine and isoniazid. Adjust doses as necessary</p> \n<p><b>Discussion</b> One case report describes development of CNS toxicity (characterized by hypersomnolence, asterixis, and abnormal findings on brain MRI) in a 69 year old woman taking cycloserine (500 mg daily) and isoniazid (400 mg daily) as part of an antituberculosis regimen.<sup>1</sup> Discontinuation of cycloserine was followed by symptom reduction within days and complete remittance within 1 month. In one cohort, combined therapy with isoniazid and cycloserine resulted in CNS toxicity (dizziness, drowsiness, unstable gait) in 9 of 11 patients, compared to 1 patient receiving cycloserine therapy alone.<sup>2</sup> <br><br>This interaction is likely the result of additive CNS toxicity of the isoniazid and cycloserine. One clinical study in patients with tuberculosis showed no impact of cycloserine on metabolism or urinary excretion of isoniazid.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kwon HM, Kim HK, Cho J, “Cycloserine-Induced Encephalopathy: Evidence on Brain MRI,” <i>Eur J Neurol</i>, 15(7):e60-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18484995\">[PubMed 18484995]</a></p>\n<p>2. Mattila MJ, Nieminen E and Tiitinen H, “Serum Levels, Urinary Excretion, and Side-Effects of Cycloserine in the Presence of Isoniazid and P-Aminosalicylic Acid,” <i>Scand J Resp Dis</i>, 1969, 50:291-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5380786\">[PubMed 5380786]</a></p>\n<p>3. Venho VM and Koskinen R, “The Effect of Pyrazinamide, Rifampicin and Cycloserine on the Blood Levels and Urinary Excretion of Isoniazid,” <i>Ann Clin Res</i>, 1971, 3(5):277-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5156629\">[PubMed 5156629]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3037":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Cyproheptadine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cyproheptadine may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of selective serotonin reuptake inhibitors if cyproheptadine is initiated/dose increased, or increased effects if cyproheptadine is discontinued/dose decreased.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine*, FluvoxaMINE, PARoxetine*, Sertraline, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Acting as a serotonin antagonist, cyproheptadine administration has been shown to cause a return of depressive symptoms within a couple of days of initiation in patients previously controlled on fluoxetine or paroxetine.<sup>1,2,3</sup> The cyproheptadine was added in each case to treat anorgasmia due to SSRI treatment. Not all patients experience the noted effects of this pharmacologic antagonism.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Feder R, “Reversal of Antidepressant Activity of Fluoxetine by Cyproheptadine in Three Patients,” <i>J Clin Psychiatry</i>, 1991, 52:163-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2016249\">[PubMed 2016249]</a></p>\n<p>2. Goldbloom DS and Kennedy SH, “Adverse Interaction of Fluoxetine and Cyproheptadine in Two Patients With Bulimia Nervosa,” <i>J Clin Psychiatry</i>, 1991, 52:261-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2055898\">[PubMed 2055898]</a></p>\n<p>3. Christensen RC, “Adverse Interaction of Paroxetine and Cyproheptadine,” <i>J Clin Psychiatry</i>, 1995, 56:433-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665546\">[PubMed 7665546]</a></p>\n<p>4. McCormick S, Olin J, and Brotman AW, “Reversal of Fluoxetine-Induced Anorgasmia by Cyproheptadine in Two Patients,” <i>J Clin Psychiatry</i>, 1990, 51:383-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2211550\">[PubMed 2211550]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3038":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Danazol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Danazol may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of simvastatin with danazol is contraindicated. Do not exceed 20 mg per day of lovastatin if combined with danazol. Monitor for increased statin toxicities (eg, myopathy, rhabdomyolysis) if combined with danazol. Fluvastatin, pravastatin, and rosuvastatin may provide lower risk alternatives. Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Lovastatin*, Red Yeast Rice, Simvastatin<br><b>Exceptions</b> Fluvastatin, Pitavastatin, Pravastatin, Rosuvastatin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports suggest an increased risk of rhabdomyolysis with concomitant use of danazol and simvastatin or lovastatin (major CYP3A4 substrates).<sup>1,2,3,4</sup> In 2 case studies, an 80-year-old male and a 68-year-old male were diagnosed with severe rhabdomyolysis after taking danazol (600 mg daily) and simvastatin (40 mg daily) concomitantly for at least 3 weeks.<sup>1,2</sup> Other reports describe a 91-year-old male and a 59-year-old female who presented with rhabdomyolysis and were found to be taking danazol (400 mg to 600 mg daily) and lovastatin (40 mg daily) for approximately 6 weeks.<sup>3,4</sup> <br><br>Simvastatin prescribing information specifically lists concurrent use of danazol as contraindicated due to evidence that this combination increases the risk for severe muscle toxicities.<sup>5</sup> Lovastatin prescribing information warns not to exceed 20 mg daily if combined with danazol and to carefully weigh the benefits of lovastatin use against the risks.<sup>6</sup><br><br>This interaction may be due to inhibition of CYP3A4 by danazol, resulting in an increase in serum statin concentrations and subsequent toxicity. In such a scenario, fluvastatin, pravastatin, and rosuvastatin would likely be unaffected by danazol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stankovic I, Vlahovic-Stipac A, Putnikovic B, Cvetkovic Z, Neskovic AN. Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis. <i>Clin Ther</i>. 2010;32(5):909-914. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20685498\">[PubMed 20685498]</a></p>\n<p>2. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. <i>Can J Clin Pharmacol</i>. 2003;10(4):172-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14712320\">[PubMed 14712320]</a></p>\n<p>3. Khanna S, Mundell WC. Rhabdomyolysis associated with co-administration of danazol and lovastatin. <i>Br J Clin Pharmacol</i>. 2011;72(1):166-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21223355\">[PubMed 21223355]</a></p>\n<p>4. Hsieh CY, Chen CH. Rhabdomyolysis and pancreatitis associated with coadministration of danazol 600 mg/d and lovastatin 40 mg/d. <i>Clin Ther</i>. 2008;30(7):1330-1335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18691993\">[PubMed 18691993]</a></p>\n<p>5. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>6. Altoprev (lovastatin) [prescribing information]. Zug, Switzerland: Covis Pharma; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3039":"<p><b>Title</b> Vitamin K Antagonists / Androgens</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of coumarin derivatives if an androgen is initiated/dose increased, or decreased effects if an androgen is discontinued/dose decreased. Significant reductions in anticoagulant dosage may be needed during concomitant therapy.</p>\n<div>\n <p><b>Androgens Interacting Members</b> Danazol*, Fluoxymesterone, Mesterolone, MethylTESTOSTERone*, Nandrolone, Oxandrolone*, Oxymetholone*, Testosterone*</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Prothrombin time increased to 168 seconds within 3 weeks in a patient following initiation of danazol (400 mg/day).<sup>1</sup> Other reports involving danazol have demonstrated hypoprothrombinemia within 2 days of starting danazol.<sup>2,3</sup> Oxymethalone administration (15 mg/day) was associated with supratherapeutic anticoagulant effects in 6 patients taking either warfarin or phenindione.<sup>4</sup> The AUC of S-warfarin was increased more than 2.5-fold in 15 normal subjects when coadministered with oxandrolone (5mg or 10mg twice daily).<sup>5</sup> Participants required a reduction in warfarin dosage of approximately 80% to maintain target INR. Several additional reports including these and other androgens (stanozolol, methyltestosterone, and testosterone vaginal ointment) with warfarin, dicumarol, and other anticoagulants, have been published.<sup>6,7,8,9,10</sup> The mechanism of these effects is unknown. Proposed mechanisms include: Androgen-induced increases in antithrombin III or protein C; or decreased synthesis/increased destruction of clotting factors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Goulbourne AI and MacLeod DAD, “An Interaction Between Danazol and Warfarin,” <i>Br J Obst Gyn</i>, 1981, 88:950-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7272269\">[PubMed 7272269]</a></p>\n<p>2. Meeks ML, Mahaffey KW, and Katz MD, “Danazol Increases the Anticoagulant Effect of Warfarin,” <i>Ann Pharmacother</i>, 1992, 26:641-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1591422\">[PubMed 1591422]</a></p>\n<p>3. Small M, Peterkin M, Lowe GD, et al, “Danazol and Oral Anticoagulants,” <i>Scott Med J</i>, 1982, 27:331-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7146883\">[PubMed 7146883]</a></p>\n<p>4. Longridge RG, Gillam PM, and Barton GM, “Decreased Anticoagulant Tolerance with Oxymetholone,” <i>Lancet</i>, 1971, 2(7715):90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4103994\">[PubMed 4103994]</a></p>\n<p>5. Oxandrin [package insert]. Greenville, NC: Savient Pharmaceuticals Inc, 2004.</p>\n<p>6. Robinson BH, Hawkins JB, Ellis JE, et al, “Decreased Anticoagulant Tolerance With Oxymetholone,” <i>Lancet</i>, 1971, 1(7713):1356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4103421\">[PubMed 4103421]</a></p>\n<p>7. Edwards MS and Curtis JR, “Decreased Anticoagulant Tolerance With Oxymetholone,” <i>Lancet</i>, 1971, 2(7717):221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4104889\">[PubMed 4104889]</a></p>\n<p>8. Shaw PW and Smith AM, “Possible Interaction of Warfarin and Stanozolol,” <i>Clin Pharm</i>, 1987, 6:500-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3690998\">[PubMed 3690998]</a></p>\n<p>9. Husted S, Andreasen F, and Foged L, “Increased Sensitivity to Phenprocoumon During Methyltestosterone Therapy,” <i>Eur J Clin Pharmacol</i>, 1976, 10:209.</p>\n<p>10. Lorentz S and McWeibert RT, “Potentiation of Warfarin Anticoagulation by Topical Testosterone Ointment,” <i>Clin Pharm</i>, 1985, 4:332-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4006400\">[PubMed 4006400]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3042":"<p><b>Title</b> Delavirdine / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Delavirdine. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Delavirdine prescribing information recommends separating doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study cited in delavirdine prescribing information, the AUC of delavirdine (300 mg single oral dose) was decreased 44% when administered simultaneously with an aluminum/magnesium-containing antacid.<sup>1</sup> A second report showed a 50% lower AUC of delavirdine (400 mg orally three times daily) in patients with spontaneous hypoacidity (gastric pH 3 or greater) compared to patients without hypoacidity.<sup>2</sup> <br><br>The mechanism of this interaction is unknown. Based on the data above, acid reduction may play a central role rather than binding/chelation or other mechanisms. Prescribing information for delavirdine states that other acid reducing agents (H2 receptor antagonists and proton pump inhibitors) may also reduce absorption of delavirdine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rescriptor (delavirdine). Kalamazoo, MI: Pharmacia &amp; Upjohn Company, November 2008.</p>\n<p>2. Shelton MJ, Hewitt RG, Adams JM, et al, “Delavirdine Malabsorption in HIV-Infected Subjects With Spontaneous Gastric Hypoacidity,” <i>J Clin Pharmacol</i>, 2003, 43(2):171-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12616670\">[PubMed 12616670]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3043":"<p><b>Title</b> Tricyclic Antidepressants / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of tricyclic antidepressants if a protease inhibitor is initiated or the dose is increased, or decreased effects if a protease inhibitor is discontinued or the dose is decreased.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir*, Saquinavir, Tipranavir</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine*, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The manufacturer of ritonavir describes a 145% increase in desipramine AUC (single 100 mg dose) when administered following a 12-day course of ritonavir (500 mg every 12 hours).<sup>1</sup> Low-dose ritonavir (100mg twice daily x 2 weeks) increased desipramine AUC by 26% in a study of 13 healthy volunteers.<sup>2</sup><br><br>The presumed mechanism is inhibition of CYP2D6 by ritonavir, reducing desipramine metabolism.<sup>1,2,3</sup> Other protease inhibitors would be expected to affect desipramine, as well as other tricyclics, the same way.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Norvir [package insert]. North Chicago, IL: Abbott Laboratories, 2000.</p>\n<p>2. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al, “Effect of Low-Dose Ritonavir (100 Mg Twice Daily) on the Activity of Cytochrome P450 2d6 in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2005, 78:664-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16338282\">[PubMed 16338282]</a></p>\n<p>3. Spina E, Gitto C, Avenoso A, et al, “Relationship between Plasma Desipramine Levels, Cyp2d6 Phenotype and Clinical Response to Desipramine: A Prospective Study,” <i>Eur J Clin Pharmacol</i>, 1997, 51:395-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9049581\">[PubMed 9049581]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3044":"<p><b>Title</b> Amphetamines / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid amphetamines during and within 14 days of discontinuation of monoamine oxidase inhibitors. Labeling for some amphetamine products in the US and Canada lists such use as contraindicated.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine*, Lisdexamfetamine, Methamphetamine*, Phendimetrazine, Phentermine</p>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Methylene Blue, Moclobemide, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine*<br><b>Exceptions</b> Linezolid, Tedizolid</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Nonselective monoamine oxidase inhibitors (MAOIs) cause an accumulation of norepinephrine within adrenergic neurons. Of particular importance are the neurons in the sympathetic system that innervate arterial blood vessels. Under such circumstances, the administration of an amphetamine (or any other indirect acting sympathomimetic) will cause the release of the stored, excess norepinephrine, and a subsequent exaggerated constriction of blood vessels - thus an exaggerated increase in blood pressure.<sup>1,2,3,4,5,6</sup> The hypertensive reactions can occur within minutes of amphetamine administration. Fatalities have occurred. Hyperpyrexia, with hypertension, has also been reported with tranylcypromine and dextroamphetamine.<sup>7</sup><br><br>The pressor response to dextroamphetamine (and tyramine) were increased two- to threefold in 4 hypertensive patients within 6 days of concomitant treatment with furazolidone (400 mg/day).<sup>8</sup> The effects were increased 10-fold after 13 days of concomitant therapy. The mechanism of this interaction appears related to the ability of furazolidone to manifest significant monoamine oxidase inhibitor (MAOI) activity over the course of 5-10 days. The MAOI activity might be due to a furazolidone metabolite.<sup>9,10</sup> The extent of MAOI activity can be similar to that of common MAOI agents (eg, tranylcypromine).<br><br>The effect of selective MAOIs on amphetamine toxicity is likely less than with nonselective products, but great caution is still advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lloyd JT and Walker DR, “Death After Combined Dexamphetamine and Phenelzine,” <i>Br Med J</i>, 1965, 2:168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14304064\">[PubMed 14304064]</a></p>\n<p>2. Zeck P, “The Dangers of Some Antidepressant Drugs,” <i>Med J Aust</i>, 1961, 2:607.</p>\n<p>3. MacDonald R, “Tranylcypromine,” <i>Lancet</i>, 1963, i:269.</p>\n<p>4. Mason A, “Fatal Reaction Associated With Tranylcypromine and Methylamphetamine,” <i>Lancet</i>, 1962, i:1073.</p>\n<p>5. Dally PJ, “Fatal Reaction Associated With Tranylcypromine and Methylamphetamine,” <i>Lancet</i>, 1962, i:1235.</p>\n<p>6. Nymark M and Nielsen IM, “Reactions Due to the Combination of MAOIs With Thymoleptics, Pethidine, or Methylamphetamine,” <i>Lancet</i>, 1963, ii:524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14065430\">[PubMed 14065430]</a></p>\n<p>7. Krisko I, Lewis E and Johnson JR, “Severe Hyperpyrexia Due to Tranylcypromine-Amphetamine Toxicity,” <i>Ann Intern Med</i>, 1969, 70:559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5775035\">[PubMed 5775035]</a></p>\n<p>8. Pettinger WA and Oates JA, “Supersensitivity to Tyramine During Monoamine Oxidase Inhibition in Man. Mechanism at the Level of the Adrenergic Neurone,” <i>Clin Pharmacol Ther</i>, 1968, 9:341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5649986\">[PubMed 5649986]</a></p>\n<p>9. Pettinger WA, Soyangco F, and Oates JA, “Inhibition of Monoamine Oxidase in Man by Furazolidone,” <i>Clin Pharmacol Ther</i>, 1968, 9:442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5655478\">[PubMed 5655478]</a></p>\n<p>10. Stern IJ, Hollifield RD, Wild S, et al, “The Anti-Monoamine Oxidase Effects of Furazolidone,” <i>J Pharmacol Exp Ther</i>, 1967, 156:492-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6028876\">[PubMed 6028876]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3045":"<p><b>Title</b> Dextromethorphan / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consideration should be given to avoiding the concomitant use of dextromethorphan and selective serotonin reuptake inhibitors (SSRIs), and in particular fluoxetine and paroxetine. Monitor for signs/symptoms of serotonin syndrome (e.g., tremor, diaphoresis, incoordination, myoclonus, etc.) or other toxic effects of dextromethorphan if such a combination is used. SSRIs other than fluoxetine and paroxetine may be safer, particularly at lower doses, due to lesser CYP2D6 inhibition, but the possibility of a more direct serotonergic interaction remains, and caution is still advised. It is also important to note that the risk for an interaction may persist for several weeks following the discontinuation of an SSRI, and particularly after fluoxetine discontinuation, given the long half-lives of both fluoxetine and its active metabolite.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine*, PARoxetine*, Sertraline, Vilazodone, Vortioxetine<br><b>Exception</b> FluvoxaMINE</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The interaction between dextromethorphan (DM) and the selective serotonin reuptake inhibitor (SSRI) antidepressants appears to involve both a pharmacodynamic and pharmacokinetic mechanism.<br><br>The pharmacodynamic interaction appears to be an additive or synergistic effect on serotonin concentrations/effects that could lead to serotonin syndrome or other adverse CNS effects. Several case reports have described patients with evidence of serotonin syndrome that was attributed to concurrent DM and an SSRI (including escitalopram, fluoxetine, paroxetine, and sertraline).<sup>1,2,3</sup> An additional report describes the development of visual hallucinations that were presumed to be caused by concomitant administration of fluoxetine (20 mg/day) and dextromethorphan (2 teaspoonfuls for 2 doses).<sup>4</sup><br><br>Regarding the potential pharmacokinetic interaction between these agents, several studies have demonstrated that the SSRIs fluoxetine and paroxetine were potent inhibitors of DM metabolism,<sup>5,6,7,8</sup> and that sertraline and fluvoxamine were also capable of inhibiting DM metabolism but were notably weaker inhibitors.<sup>5,6,9,10</sup><br><br>The likely mechanism for this interaction is SSRI-mediated inhibition of the CYP2D6 metabolism of DM. Based on studies evaluating their effects on CYP2D6 activity, citalopram and escitalopram are likely only weak inhibitors of DM metabolism (relatively similar to sertraline and fluvoxamine and less potent than fluoxetine or paroxetine),<sup>11,12</sup> and based on in vitro data, vilazodone is unlikely to interact with DM to any significant degree.<sup>13</sup> Of note, given the long half-life of the interacting SSRIs, a potential interaction with DM likely remains for several weeks following cessation of a particular SSRI. In one study, a return to baseline CYP2D6 activity required an average of more than 60 days following fluoxetine discontinuation and an average of 20-25 days after paroxetine or sertraline discontinuation.<sup>14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schwartz AR, Pizon AF, Brooks DE, “Dextromethorphan-Induced Serotonin Syndrome,” <i>Clin Toxicol (Phila)</i>, 2008, 46(8):771-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19238739\">[PubMed 19238739]</a></p>\n<p>2. Navarro A, Perry C, Bobo WV, “A Case of Serotonin Syndrome Precipitated by Abuse of the Anticough Remedy Dextromethorphan in a Bipolar Patient Treated with Fluoxetine and Lithium,” <i>Gen Hosp Psychiatry</i>, 2006, 28(1):78-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16377370\">[PubMed 16377370]</a></p>\n<p>3. Skop BP, Finkelstein JA, Mareth TR, et al, “The Serotonin Syndrome Associated With Paroxetine, An Over-the-Counter Cold Remedy and Vascular Disease,” Am J Emerg Med, 1994, 12:642-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7945606\">[PubMed 7945606]</a></p>\n<p>4. Achamallah NS, “Visual Hallucinations After Combining Fluoxetine and Dextromethorphan,” Am J Psychiatry, 1992, 149:1406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1530079\">[PubMed 1530079]</a></p>\n<p>5. Lam YW, Gaedigk A, Ereshefsky L, et al, “CYP2D6 Inhibition by Selective Serotonin Reuptake Inhibitors: Analysis of Achievable Steady-State Plasma Concentrations and the Effect of Ultrarapid Metabolism at CYP2D6,” <i>Pharmacotherapy</i>, 2002, 22(8):1001-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12173784\">[PubMed 12173784]</a></p>\n<p>6. Alfaro CL, Lam YW, Simpson J, et al, “CYP2D6 Status of Extensive Metabolizers After Multiple-Dose Fluoxetine, Fluvoxamine, Paroxetine, or Sertraline,” <i>J Clin Psychopharmacol</i>, 1999, 19(2):155-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10211917\">[PubMed 10211917]</a></p>\n<p>7. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al, “Apparent Mechanism-Based Inhibition of Human CYP2D6 In Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine,” <i>Drug Metab Dispos</i>, 2003, 31(3):289-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12584155\">[PubMed 12584155]</a></p>\n<p>8. Otton SV, Wu D, Joffe RT, et al, “Inhibition of Fluoxetine of Cytochrome P450 2D6 Activity,” Clin Pharmacol Ther, 1993, 53:401-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8477556\">[PubMed 8477556]</a></p>\n<p>9. Kashuba AD, Nafziger AN, Kearns GL, et al, “Effect of Fluvoxamine Therapy on the Activities of CYP1A2, CYP2D6, and CYP3A as Determined by Phenotyping,” <i>Clin Pharmacol Ther</i>, 1998, 64(3):257-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>10. Sproule BA, Otton SV, Cheung SW, et al, “CYP2D6 Inhibition in Patients Treated with Sertraline,” <i>J Clin Psychopharmacol</i>, 1997, 17(2):102-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10950472\">[PubMed 10950472]</a></p>\n<p>11. Preskorn SH, Greenblatt DJ, Flockhart D, et al, “Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers,” <i>J Clin Psychopharmacol</i>, 2007, 27(1):28-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17224709\">[PubMed 17224709]</a></p>\n<p>12. Jeppesen U, Gram LF, Vistisen K, et al, “Dose-Dependent Inhibition of CYP1A2, CYP2C19 and CYP2D6 by Citalopram, Fluoxetine, Fluvoxamine and Paroxetine,” <i>Eur J Clin Pharmacol</i>, 1996, 51(1):73-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8880055\">[PubMed 8880055]</a></p>\n<p>13. Prescribing information. Viibryd (vilazodone). New Haven, CT: Trovis Pharmaceuticals LLC, January 2010.</p>\n<p>14. Liston HL, DeVane CL, Boulton DW, et al, “Differential Time Course of Cytochrome P450 2D6 Enzyme Inhibition by Fluoxetine, Sertraline, and Paroxetine in Healthy Volunteers,” <i>J Clin Psychopharmacol</i>, 2002, 22(2):169-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11910262\">[PubMed 11910262]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3046":"<p><b>Title</b> Dextromethorphan / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of dextromethorphan and monoamine oxidase inhibitors should be avoided. Alternative antitussive therapy should be used. In general, furazolidone, linezolid, tedizolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide*, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Death (associated with coma, hyperpyrexia, and hypotension) in a phenelzine-treated patient has been blamed on the additional ingestion of a cough syrup (single dose) containing dextromethorphan.<sup>1</sup> Other cases of fatalities and significant morbidity (eg, myoclonus, rigidity, apnea, urinary retention, nausea) have been reported with phenelzine and moclobemide.<sup>2,3,4</sup> The mechanism of these interactions is unclear, but appears to be related to an increase in serotonin activity during concomitant use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rivers N and Horner B, “Possible Lethal Reaction Between Nardil and Dextromethorphan,” <i>Can Med Assoc J</i>, 1970, 103:85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20311659\">[PubMed 20311659]</a></p>\n<p>2. Shamsie JC and Barriga C, “The Hazards of Use of Monoamine Oxidase Inhibitors in Disturbed Adolescents,” <i>Can Med Ass J</i>, 1971, 104:715. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5550381\">[PubMed 5550381]</a></p>\n<p>3. Sovner R and Wolfe J, “Interaction Between Dextromethorphan and Monoamine Oxidase Inhibitor Therapy With Isocarboxazid,” <i>New Eng J Med</i>, 1988, 319:1671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3200285\">[PubMed 3200285]</a></p>\n<p>4. Nierenberg DW and Semprebon M, “The Central Nervous System Serotonin Syndrome,” <i>Clin Pharmacol Ther</i>, 1993, 53:84-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8257462\">[PubMed 8257462]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3047":"<p><b>Title</b> Dextromethorphan / QuiNIDine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Genotype</b>: This interaction is less likely to be significant in those homozygous for <i>CYP2D6</i> loss-of-function variants, in whom considerably higher dextromethorphan concentrations would be expected regardless of concurrent medications.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> QuiNIDine may increase the serum concentration of Dextromethorphan. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> In order to avoid unwanted clinical consequences of this interaction, avoid the concurrent use of these agents when possible. Note that codeine conversion to morphine is also inhibited by quinidine, and thus is not likely to be an effective antitussive alternative. This combination may be intentionally used for the enhanced CNS effects of dextromethorphan, such as in the treatment of pseudobulbar affect. Monitor patients particularly closely for evidence of CNS-related toxicities during any concomitant use of dextromethorphan and qunidine (e.g., headache, insomnia, nervousness, confusion).</p> \n<p><b>Discussion</b> Several in vivo studies have shown that concurrent administration of quinidine and dextromethorphan (DM) is associated with a substantial increase in DM concentrations (up to a 43-fold increase in DM AUC) and a similarly significant decrease in dextrorphan (primary DM metabolite) concentrations.<sup>1,2,3,4,5,6</sup> This increase in DM concentrations with concurrent quinidine has also been associated with increases in the psychoactive and antitussive (though not clearly statistically significant) effects of DM.<sup>1,2</sup> Though this enhancement of the DM psychoactive effects is often an undesirable consequence of the interaction, this effect is intentionally sought with the available DM/quinidine combination product that is approved for treatment of pseudobulbar affect.<sup>7</sup><br><br>The mechanism for this interaction is potent inhibition of the CYP2D6-mediated O-demethylation of DM by quinidine.<sup>8,9</sup> Of note, patients who are CYP2D6 “poor metabolizers” due to genetic variations in the <i>CYP2D6</i> gene are likely to have higher-than-expected DM concentrations even without concurrent quinidine; however, concurrent use of quinidine in these patients is unlikely to result in any further change in DM concentrations. In fact, most studies of this interaction include only CYP2D6 “extensive metabolizers.”</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zawertailo LA, Tyndale RF, Busto U, et al, “Effect of Metabolic Blockade on the Psychoactive Effects of Dextromethorphan,” <i>Hum Psychopharmacol</i>, 2010, 25(1):71-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20041473\">[PubMed 20041473]</a></p>\n<p>2. Abdul Manap R, Wright CE, Gregory A, et al, “The Antitussive Effect of Dextromethorphan in Relation to CYP2D6 Activity,” <i>Br J Clin Pharmacol</i>, 1999, 48(3):382-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10510150\">[PubMed 10510150]</a></p>\n<p>3. Pope LE, Khalil MH, Berg JE, et al, “Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination with Quinidine in Extensive and Poor Metabolizers,” <i>J Clin Pharmacol</i>, 2004, 44(10):1132-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15342614\">[PubMed 15342614]</a></p>\n<p>4. Capon DA, Bochner F, Kerry N, et al, “The Influence of CYP2D6 Polymorphism and Quinidine on the Disposition and Antitussive Effect of Dextromethorphan in Humans,” <i>Clin Pharmacol Ther</i>, 1996, 60(3):295-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8841152\">[PubMed 8841152]</a></p>\n<p>5. Schadel M, Wu D, Otton SV, et al, “Pharmacokinetics of Dextromethorphan and Metabolites in Humans: Influence of the CYP2D6 Phenotype and Quinidine Inhibition,” <i>J Clin Psychopharmacol</i>, 1995, 15(4):263-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7593709\">[PubMed 7593709]</a></p>\n<p>6. Zhang Y, Britto M, Valderhaug KL, et al, “Dextromethorphan: Enhancing its Systemic Availability by Way of Low-Dose Quinidine-Mediated Inhibition of Cytochrome P4502D6,” <i>Clin Pharmacol Ther</i>, 1992, 51:647-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1611804\">[PubMed 1611804]</a></p>\n<p>7. Prescribing information. Neudexta (dextromethorphan and quinidine). Aliso Viejo, CA: Avanir Pharmaceuticals, Inc., 10/2010.</p>\n<p>8. Kerry NL, Somogyi AA, Bochner F, et al, “The Role of CYP2D6 in Primary and Secondary Oxidative Metabolism of Dextromethorphan: In Vitro Studies Using Human Liver Microsomes,” <i>Br J Clin Pharmacol</i>, 1994, 38(3):243-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7826826\">[PubMed 7826826]</a></p>\n<p>9. Broly F, Libersa C, Lhermitte M, et al, “Effect of Quinidine on the Dextromethorphan O-Demethylase Activity of Microsomal Fractions from Human Liver,” <i>Br J Clin Pharmacol</i>, 1989, 28(1):29-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2775613\">[PubMed 2775613]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3049":"<p><b>Title</b> Vitamin K Antagonists / Thyroid Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased anticoagulant effects of vitamin K antagonists if a thyroid product is initiated/dose increased, or decreased effects if a thyroid product is discontinued/dose decreased.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine*, Liotrix, Thyroid, Desiccated</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Initiation of levothyroxine was not associated with any change in warfarin sensitivity (measured as warfarin dose/INR ratio) and was associated with a small decrease in the average number of pharmacist-patient contacts in the 90 days following initiation according to a retrospective cohort study of 119 patients evaluating warfarin dose, INR, and pharmacist-patient contacts in both the 90 days prior to and 90 days following initiation of levothyroxine in patients previously stable on warfarin.<sup>1</sup> The average warfarin dose requirement was only 2% lower in the 90 days following levothyroxine initiation, and their findings were not significantly different according to dose of levothyroxine or severity of initial hypothyroidism. A retrospective case control analysis of a Canadian health database also concluded that warfarin-treated patients were not at increased odds of hospitalization for hemorrhage in the first 30 days after initiation of levothyroxine (N=10,532 with hemorrhage and 40,693 without hemorrhage, but only 84 initiating levothyroxine in either group).<sup>2</sup> Analyses of more distant levothyroxine exposure (i.e., initiation at 31-60 days prior or 61-90 days prior) also found no increase in the odds of hospitalization for hemorrhage.<br><br>In contrast, 7 of 11 warfarin-treated patients required a warfarin dose reduction in the 4 weeks following dextrothyroxine initiation, with an average dose reduction of approximately 18% among those requiring any reduction (range = 9% to 33% reductions).<sup>3</sup> The overall prothrombin response to single warfarin doses was greater following initiation of liothyronine in a study of 7 patients with myxedema who were studied prior to liothyronine initiation and again at 3 and 6 months after initiation.<sup>4</sup> The peak prothrombin time response was only non-significantly higher (by 19% to 38%) following liothyronine initiation, and the warfarin half-life was not significantly changed. Several case reports, case series, and studies also describe patients with an enhanced anticoagulant response to vitamin K antagonists (e.g., warfarin) in hyperthyroid patients, and a decreased response in hypothyroid patients, compared to euthyroid patients.<sup>5,6,7,8,9,10,11,12,13,14,15,16,17,18</sup> Very few of these studies and case reports describe patients with bleeding attributed to this purported interaction,<sup>3,11</sup> and the degree to which these reports are describing a drug-drug versus a drug-disease interaction is not clear.<sup>5,6,15,16</sup><br><br>The mechanism of this purported association is not clear. Several hypotheses have been proposed: a) hypothyroid patients may metabolize vitamin K-dependent clotting factors more slowly than euthyroid patients (the converse was not demonstrated in a small sample of patients with hyperthyroidism);<sup>14,19</sup> b) warfarin protein binding may be decreased in hyperthyroid patients;<sup>20</sup> c) thyroid hormone may increase the affinity of vitamin K-dependent epoxide reductase for warfarin;<sup>10</sup> and d) although currently having only very limited support, thyroid autoantibodies may modify warfarin effects when present.<sup>21</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wood MD, Delate T, Clark M, Clark N, Horn JR, Witt DM. An evaluation of the potential drug interaction between warfarin and levothyroxine. <i>J Thromb Haemost</i>. 2014 Jun 9 (Epub ahead of print). doi: 10.1111/jth.12626. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24913218\">[PubMed 24913218]</a></p>\n<p>2. Pincus D, Gomes T, Hellings C, et al. A population-based assessment of the drug interaction between levothyroxine and warfarin. <i>Clin Pharmacol Ther</i>. 2012;92(6):766-770. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23093318\">[PubMed 23093318]</a></p>\n<p>3. Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. <i>N Engl J Med</i>. 1962;266:76-79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14482918\">[PubMed 14482918]</a></p>\n<p>4. Rice AJ, McIntosh TJ, Fouts JR, Brunk SF, Wilson WR. Decreased sensitivity to warfarin in patients with myxedema. <i>Am J Med Sci</i>. 1971;262(4):211-215. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5142577\">[PubMed 5142577]</a></p>\n<p>5. Vagenakis AG, Cote R, Miller ME, Braverman LE, Stohlman F Jr. Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis. <i>Johns Hopkins Med J</i>. 1972;131(1):69-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4114451\">[PubMed 4114451]</a></p>\n<p>6. Self T, Weisburst M, Wooten E, Straughn A, Oliver J. Warfarin-induced hypoprothrombinemia. Potentiation by hyperthyroidism. <i>JAMA</i>. 1975;231(11):1165-1166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172818\">[PubMed 1172818]</a></p>\n<p>7. Walters MB. The relationship between thyroid function and anticoagulant thrapy. <i>Am J Cardiol</i>. 1963;11:112-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13998701\">[PubMed 13998701]</a></p>\n<p>8. Akin F, Yaylali GF, Bastemir M, Yapar B. Effect of methimazole on warfarin anticoagulation in a case of Graves' disease. <i>Blood Coagul Fibrinolysis</i>. 2008;19(1):89-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18180622\">[PubMed 18180622]</a></p>\n<p>9. Busenbark LA, Cushnie SA. Effect of Graves' disease and methimazole on warfarin anticoagulation. <i>Ann Pharmacother</i>. 2006;40(6):1200-1203. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16735660\">[PubMed 16735660]</a></p>\n<p>10. Solomon HM, Schrogie JJ. Change in receptor site affinity: a proposed explanation for the potentiating effect of D-thyroxine on the anticoagulant response to warfarin. <i>Clin Pharmacol Ther</i>. 1967;8(6):797-799. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6059285\">[PubMed 6059285]</a></p>\n<p>11. Costigan DC, Freedman MH, Ehrlich RM. Potentiation of oral anticoagulant effect by L-thyroxine. <i>Clin Pediatr (Phila)</i>. 1984;23(3):172-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6697623\">[PubMed 6697623]</a></p>\n<p>12. Jones RJ, Cohen L. Sodium dextro-thyrxine in coronary disease and hypercholesteremia. <i>Circulation</i>. 1961;24:164-170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13790583\">[PubMed 13790583]</a></p>\n<p>13. Stephens MA, Self TH, Lancaster D, Nash T. Hypothyroidism: effect on warfarin anticoagulation. <i>South Med J</i>. 1989;82(12):1585-1586. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2595433\">[PubMed 2595433]</a></p>\n<p>14. Chute JP, Ryan CP, Sladek G, Shakir KM. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism. <i>Endocr Pract</i>. 1997;3(2):77-79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15251480\">[PubMed 15251480]</a></p>\n<p>15. Woeber KA, Warner I. Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis. <i>West J Med</i>. 1999;170(1):49-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9926737\">[PubMed 9926737]</a></p>\n<p>16. Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. <i>Medicine (Baltimore)</i>. 2004;83(2):107-113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15028964\">[PubMed 15028964]</a></p>\n<p>17. Bucerius J, Joe AY, Palmedo H, Reinhardt MJ, Biersack HJ. Impact of short-term hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy. <i>Thyroid</i>. 2006;16(4):369-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16646683\">[PubMed 16646683]</a></p>\n<p>18. Pavani A, Naushad SM, Mishra RC, et al. Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. <i>Pharmacogenomics</i>. 2012;13(8):869-878. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22676192\">[PubMed 22676192]</a></p>\n<p>19. van Oosterom AT, Kerkhoven P, Veltkamp JJ. Metabolism of the coagulation factors of the prothrombin complex in hypothyroidism in man. <i>Thromb Haemost</i>. 1979;41(2):273-285. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=473111\">[PubMed 473111]</a></p>\n<p>20. Feely J, Stevenson IH, Crooks J. Altered plasma protein binding of drugs in thyroid disease. <i>Clin Pharmacokinet</i>. 1981;6(4):298-305. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7249488\">[PubMed 7249488]</a></p>\n<p>21. Dentali F, Rancan E, van Zaane B, et al. The effect of thyroid autoantibodies on warfarin stability. <i>Thromb Res</i>. 2010;126(1):e61-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19822352\">[PubMed 19822352]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3050":"<p><b>Title</b> Phenytoin / Diazoxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diazoxide may decrease the serum concentration of Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of phenytoin if diazoxide is initiated/dose increased, or increased effects if diazoxide is discontinued/dose decreased. Free phenytoin concentrations may be a preferred means of monitoring therapy as protein binding displacement may be involved in this interaction, and total phenytoin concentrations may not be an adequate reflection of how much “active” (i.e., free or unbound) phenytoin is present.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations were significantly decreased in 3 pediatric patients during concomitant therapy with diazoxide.<sup>1,2,3</sup> Serum concentrations increased (and needed phenytoin dosages decreased) upon discontinuation of diazoxide. Upon rechallenge, one patient's serum phenytoin concentration decreased to undetectable levels and the patient experienced seizures.<sup>1,2</sup> The mechanism of this interaction is uncertain, but there was evidence that diazoxide decreased phenytoin protein binding.<sup>2</sup> This decreased protein binding together with evidence of increased urinary excretion of the major phenytoin metabolite<sup>2</sup> suggests that protein binding displacement by diazoxide led to greater clearance (because greater proportion of unbound phenytoin available for metabolism) and a decrease in total phenytoin concentrations. Assessment of free phenytoin concentrations would likely be a preferable means of monitoring therapy in patients using this combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Roe TF, Podosin RL, and Blaskovics MR, “Drug Interaction. Diazoxide and Diphenylhydantoin,” <i>Pediatr Res</i>, 1975, 9:285.</p>\n<p>2. Roe TF, Podosin RL, and Blaskovics ME, “Drug Interaction. Diazoxide and Diphenylhydantoin,” <i>J Pediatr</i>, 1975, 87:480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1165331\">[PubMed 1165331]</a></p>\n<p>3. Petro DJ, Vannucci RC, and Kulin HE, “Diazoxide-Diphenylhydantoin Interaction,” <i>J Pediatr</i>, 1976, 89:331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=940040\">[PubMed 940040]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3051":"<p><b>Title</b> Diazoxide / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Diazoxide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for excess hyperglycemia, hyperuricemia, and/or hypotension during concomitant use of diazoxide and thiazide diuretics.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Severe hyperglycemia manifested in a patient during concomitant use of diazoxide and trichlormethiazide.<sup>1</sup> Diazoxide prescribing information cautions that concurrent use with a thiazide diuretic may result in greater hyperuricemic and/or antihypertensive effects.<sup>2</sup><br><br>Both diazoxide and thiazide diuretics are somewhat similar structurally, and both have the potential to cause hyperglycemia, hyperuricemia, and/or hypotension. With concurrent use, the risks for any of these effects could be increased.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Seltzer HS and Allen EW, “Hyperglycaemia and Inhibition of Insulin Secretion During Administration of Diazoxide and Trichlormethiazide in Man,” <i>Diabetes</i>, 1969, 18:19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=57161863\">[PubMed 57161863]</a></p>\n<p>2. Prescribing information. Diastat (diazoxide). Kenilworth, NJ: Schering Corporation, 05/2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3052":"<p><b>Title</b> Lithium / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider reducing the dosage of lithium upon initiation of a nonsteroidal anti-inflammatory agent (NSAID). Monitor for increased therapeutic/toxic effects of lithium if an NSAID is initiated/dose increased, or decreased effects if an NSAID is discontinued/dose decreased.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib*, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid*, Meloxicam*, Morniflumate, Nabumetone, Naproxen*, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic)*, Piroxicam (Topical), Propyphenazone, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen<br><b>Exception</b> Sulindac</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum lithium concentrations are typically increased by coadministration with a nonsteroidal anti-inflammatory agent (NSAID) approximately 25% to 50% (sometimes higher), with toxicity evident in many patients. Interaction evidence is available for celecoxib,<sup>1,2,3</sup> diclofenac,<sup>5</sup> flurbiprofen,<sup>5</sup> ibuprofen,<sup>7,8,9</sup> indomethacin,<sup>8,10</sup> ketorolac,<sup>11,12,13</sup> mefenamic acid,<sup>14</sup> meloxicam,<sup>15</sup> naproxen,<sup>16</sup> phenylbutazone,<sup>17</sup> piroxicam,<sup>18,19</sup>, rofecoxib,<sup>3,20,21</sup> and valdecoxib.<sup>22</sup> This interaction has not been exhibited in every patient, and may be difficult to predict.<sup>7,8,23</sup> In addition, sulindac is reported to decrease serum lithium concentrations by as much as 50% soon after therapy initiation, with subsequent normalization of serum lithium concentrations during the course of subsequent treatment days/weeks.<sup>24</sup> Other sulindac reports demonstrate no effects on lithium disposition.<sup>15,25</sup> NSAIDs appear to inhibit the renal clearance of lithium. The mechanism of this effect is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Eskalith [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2002.</p>\n<p>2. Gunja N, Graudins A, and Dowsett R, “Lithium Toxicity: A Potential Interaction With Celecoxib,” <i>Intern Med J</i>, 2002, 32(9-10):494. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12380707\">[PubMed 12380707]</a></p>\n<p>3. Phelan KM, Mosholder AD, and Lu S, “Lithium Interaction With the Cyclooxygenase 2 Inhibitors Rofecoxib and Celecoxib and Other Nonsteroidal Anti-Inflammatory Drugs,” <i>J Clin Psychiatry</i>, 2003, 64(11):1328-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14658947\">[PubMed 14658947]</a></p>\n<p>4. Slordal L, Samstad S, Bathen J, et al, “A Life-Threatening Interaction Between Lithium and Celecoxib,” <i>Br J Clin Pharmacol</i>, 2003, 55(4):413-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12680891\">[PubMed 12680891]</a></p>\n<p>5. Reimann IW and Frolich JC, “Effects of Diclofenac on Lithium Kinetics,” <i>Clin Pharmacol Ther</i>, 1981, 30:348-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7273598\">[PubMed 7273598]</a></p>\n<p>6. Hughes MB, Small RE, Brink D, et al, “The Effect of Flurbiprofen On Steady-State Plasma Lithium Levels,” <i>Pharmacotherapy</i>, 1997, 17:113-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9017771\">[PubMed 9017771]</a></p>\n<p>7. Ragheb M, Ban TA, Buchanan D, et al, “Interaction of Indomethacin and Ibuprofen With Lithium in Manic Patients Under a Steady-State Lithium Level,” <i>J Clin Psychiatry</i>, 1980, 41:397-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7440513\">[PubMed 7440513]</a></p>\n<p>8. Leftwich RB, Walker LA, Ragheb M, et al, “Inhibition of Prostaglandin Synthesis Increases Plasma Lithium Levels,” <i>Clin Res</i>, 1978, 26:291A.</p>\n<p>9. Ragheb M, “Ibuprofen Can Increase Serum Lithium Levels in Lithium-Treated Patients,” <i>J Clin Psychiatry</i>, 1987, 48:161-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3558329\">[PubMed 3558329]</a></p>\n<p>10. Frolich JC, Leftwich R, Ragheb M, et al, “Indomethacin Increases Plasma Lithium,” <i>Br Med J</i>, 1979, 1:1115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=444956\">[PubMed 444956]</a></p>\n<p>11. Langlois R and Paquette D, “Increased Serum Lithium Levels Due to Ketorolac Therapy,” <i>Can Med Assoc J</i>, 1994, 150:1455-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8168010\">[PubMed 8168010]</a></p>\n<p>12. Iyer V, “Ketorolac (Toradol) Induced Lithium Toxicity,” <i>Headache</i>, 1994, 34:442-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7928331\">[PubMed 7928331]</a></p>\n<p>13. Van Den Berg CM, Zum Brunnen TL, Cold JA, et al, “Utilization of Saliva Lithium Levels: Detection of Potential Drug-Drug Interaction With NSAIDs,” <i>Pharmacotherapy</i>, 1997, 17:1099.</p>\n<p>14. MacDonald J and Neale TJ, “Toxic Interaction of Lithium Carbonate and Mefenamic Acid,” <i>Br Med J</i>, 1988, 297:1339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3144399\">[PubMed 3144399]</a></p>\n<p>15. Turck D, Heinzel G, and Luik G, “Steady-State Pharmacokinetics of Lithium in Healthy Volunteers Receiving Concomitant Meloxicam,” <i>Br J Clin Pharmacol</i>, 2000, 50(3):197-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10971303\">[PubMed 10971303]</a></p>\n<p>16. Ragheb M and Powell AL, “Lithium Interaction With Sulindac and Naproxen,” <i>J Clin Psychopharmacol</i>, 1986, 6:150-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3711365\">[PubMed 3711365]</a></p>\n<p>17. Ragheb M, “The Interaction of Lithium With Phenylbutazone in Bipolar Affective Patients,” <i>J Clin Psychopharmacol</i>, 1990, 10:149-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2341593\">[PubMed 2341593]</a></p>\n<p>18. Kerry RJ, Owen G, and Michaelson S, “Possible Toxic Interaction Between Lithium and Piroxicam,” <i>Lancet</i>, 1983, i:418-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6130411\">[PubMed 6130411]</a></p>\n<p>19. Bikin D, Conrad KA, and Mayersohn M, “Lack of Influence of Caffeine and Aspirin on Lithium Elimination,” <i>Clin Res</i>, 1982, 30:249A.</p>\n<p>20. Lundmark J, Gunnarsson T, and Bengtsson F, “A Possible Interaction Between Lithium and Rofecoxib,” <i>Br J Clin Pharmacol</i>, 2002, 53(4):403-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11966674\">[PubMed 11966674]</a></p>\n<p>21. Ratz Bravo AE, Egger SS, Crespo S, et al, “Lithium Intoxication as a Result of an Interaction with Rofecoxib,” <i>Ann Pharmacother</i>, 2004, 38(7-8):1189-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15187206\">[PubMed 15187206]</a></p>\n<p>22. Bextra [package insert]. Chicago, IL: GD Searle LLC, 2001.</p>\n<p>23. Levin GM, Grum C, and Eisele G, “Effect of Over-the-Counter Dosages of Naproxen Sodium and Acetaminophen on Plasma Lithium Concentrations in Normal Volunteers,” <i>J Clin Psychopharmacol</i>, 1998, 18:237-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9617983\">[PubMed 9617983]</a></p>\n<p>24. Furnell MM and Davies J, “The Effect of Sulindac on Lithium Therapy,” <i>Drug Intell Clin Pharm</i>, 1986, 19:374-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4006726\">[PubMed 4006726]</a></p>\n<p>25. Ragheb MA and Powell AL, “Failure of Sulindac to Increase Serum Lithium Levels,” <i>J Clin Psychiatry</i>, 1986, 47:33-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3941055\">[PubMed 3941055]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3053":"<p><b>Title</b> Methotrexate / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use extreme caution if initiating a nonsteroidal anti-inflammatory drug (NSAID) in patients taking methotrexate. Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate. Labeling for the NSAIDs dexketoprofen and dexibuprofen specifically caution that concurrent use with methotrexate doses of 15 mg/week or more should not be used or is inadvisable. Also, the combination of methotrexate and the NSAID dipyrone must be avoided according to dipyrone product labeling. The risk may be lower with selective COX-2 inhibitors than with nonselective agents. The risk associated with lower doses of methotrexate (eg, antirheumatic therapy) is also likely to be less. If methotrexate and NSAIDs are to be used concomitantly, monitor patients for evidence of hematologic toxicity (frequent CBC), nephrotoxicity (frequent serum creatinine), and hepatotoxicity (LFTs).</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac*, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen*, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen*, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin*, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Nonsteroidal anti-inflammatory agents (NSAIDs) exhibit varying effects on the pharmacokinetics of methotrexate. Indomethacin and tolmetin have been reported to increase the AUC of methotrexate from 19% to 140% in pediatric patients.<sup>1</sup> This wide range of AUC changes likely reflects the varying doses of indomethacin, tolmetin, and methotrexate for each pediatric patient, and since AUC represents the extent of tissue exposure to methotrexate, these patients may be at increased risk of developing toxicity.<sup>1</sup> Etodolac is reported to increase methotrexate half-life by 38% without any change in AUC,<sup>2</sup> and ibuprofen may decrease methotrexate clearance by 40% to 50%.<sup>3,4</sup> In contrast, other reports conclude that ibuprofen, indomethacin, and several other NSAIDs do not significantly affect methotrexate pharmacokinetics.<sup>5,6,7,8,9,10,11,12</sup> Regardless of pharmacokinetic changes, several NSAIDs have been associated with the development of methotrexate toxicity (neutropenia, thrombocytopenia, kidney failure) as soon as a day after NSAID initiation in methotrexate-stable patients.<sup>13,14,15,16,17,18</sup> <br><br>Some NSAIDs may decrease renal excretion of methotrexate by inhibiting renal transport proteins and/or decreasing renal perfusion.<sup>19,20,21</sup> In addition, some NSAIDs may have additive toxicities with methotrexate (eg, renal toxicity with indomethacin, hematologic toxicity with phenylbutazone and dipyrone). Labeling for the NSAIDs dexketoprofen and dexibuprofen specifically caution that concurrent use with methotrexate doses of 15 mg/week or more should not be used or is inadvisable.<sup>22,23,24,25</sup> Similarly, dipyrone labeling recommends avoiding the combination of methotrexate and dipyrone.<sup>26</sup> COX-2 selective inhibitors may prove safer than nonselective agents.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate-nonsteroidal anti-inflammatory drug interaction in children with arthritis. <i>J Rheumatol</i>. 1990;17:1469-1473. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2273487\">[PubMed 2273487]</a>]</p>\n<p>2. Anaya JM, Fabre D, Bressolle F, et al. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. <i>J Rheumatol</i>. 1994;21:203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8182625\">[PubMed 8182625]</a></p>\n<p>3. Tracy TS, Jones DR, Hall SK, Brater DC, Bradley JD, Krohn K. The effect of NSAIDs on methotrexate disposition in patients with rheumatoid arthritis. <i>Clin Pharmacol Ther</i>. 1990;47:138 [Abstract 54].</p>\n<p>4. Tracy TS, Krohn K, Jones DR ,Bradley JD, Hall SD, Brater DC. The effects of salicylate, ibuprofen, and naproxen on the disposition of metotrexate in patients with rheumatoid arthritis. <i>Eur J Clin Pharmacol</i>. 1992;42:121-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618240\">[PubMed 1618240]</a></p>\n<p>5. Karin A, Tolbert D, Piergies A, et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin. <i>Arthritis Rheum</i>. 1998;41(Suppl 9):S315. [Abstract]</p>\n<p>6. Iqbal MP, Baig JA, Ali AA,Niazi SK, Mehboobali N, Hussain MA. The effects of nonsteroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. <i>Biopharm Drug Dispos</i>. 1998;19:163-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9569999\">[PubMed 9569999]</a></p>\n<p>7. Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. <i>J Rheumatol</i>. 1990;17:1008-1010. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2213774\">[PubMed 2213774]</a></p>\n<p>8. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam, and flurbiprofen in patients with rheumatoid arthritis. <i>Br J Clin Pharmac</i>. 1994;37:453-456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8054251\">[PubMed 8054251]</a></p>\n<p>9. Christophidis N, Dawson TM, Angelis P, et al. A double-blind, randomized, placebo controlled pharmacokinetic and clinical study of the interaction of ketoprofen and naproxen with methotrexate in rheumatoid arthritis. <i>Arthritis Rheum</i>. 1994; 37(Suppl 9):S252. [Abstract] </p>\n<p>10. Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. <i>Clin Pharmacol Ther</i>. 1990;47:540-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2328562\">[PubMed 2328562]</a></p>\n<p>11. Combe B, Edno L, Lafforgue P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. <i>Br J Rheumatol</i>. 1995;34:421-428. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7788170\">[PubMed 7788170]</a></p>\n<p>12. Huebner G, Sander D, Degner FL, Turck D, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. <i>J Rheumatol</i>. 1997;24:845-851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9150070\">[PubMed 9150070]</a></p>\n<p>13. Frenia ML, Long KS. Methotrexate and nonsteroidal anti-inflammatory drug interaction. <i>Ann Pharmacother</i>. 1992;26:234-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1554938\">[PubMed 1554938]</a></p>\n<p>14. Cassano W. Serious methotrexate toxicity caused by interaction with ibuprofen. <i>Am J Ped Hematol/Oncol</i>. 1989;11:481-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2618985\">[PubMed 2618985]</a></p>\n<p>15. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. <i>Lancet</i>. 1986;1(8475):256-258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2868265\">[PubMed 2868265]</a></p>\n<p>16. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. <i>Lancet</i>. 1986;1(8494):1390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2872507\">[PubMed 2872507]</a></p>\n<p>17. Adams JD, Hunter G. Drug interaction in psoriasis. <i>Aust J Dermatol</i>. 1976;17:39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1022213\">[PubMed 1022213]</a></p>\n<p>18. Mayall B, Poggi G, Parkin JD. Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. <i>Med J Aust</i>. 1991;155:480-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1921820\">[PubMed 1921820]</a></p>\n<p>19. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4 mediated methotrexate transport. <i>J Pharmacol Exp Ther</i>. 2007;320(1):229-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005917\">[PubMed 17005917]</a></p>\n<p>20. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. <i>J Pharmacol Exp Ther</i>. 2004;309(1):226-234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14722319\">[PubMed 14722319]</a></p>\n<p>21. Takeda M, Khamdang S, Narikawa S. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. <i>J Pharmacol Exp Ther</i>. 2002;302(2):666-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12130730\">[PubMed 12130730]</a></p>\n<p>22. Kera (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>23. Enantyum (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>24. Ketesse (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p>25. Sonifen (dexibuprofen) [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201403363. Accessed March 15, 2017.</p>\n<p>26. Anador (dipyrone) [summary of product characteristics]. Itapeceria da Serra, Sao Paulo, Brazil: Boehringer Ingelheim Brazil Chemistry and Farm Ltda; 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3054":"<p><b>Title</b> Cardiac Glycosides / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations and toxic effects (e.g., gastrointestinal distress, weakness, dizziness, arrhythmia) of cardiac glycosides if a macrolide antibiotic is initiated/dose increased, or decreased serum concentrations and therapeutic effects if a macrolide antibiotic is discontinued/dose decreased.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin*, Digoxin*</p>\n <p><b>Macrolide Antibiotics Interacting Members</b> Azithromycin (Systemic)*, Clarithromycin*, Erythromycin (Systemic)*, Telithromycin*<br><b>Exceptions</b> Fidaxomicin, Roxithromycin, Spiramycin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Numerous case reports describe patients receiving digoxin who experienced increased digoxin serum concentrations (up to 4 fold) and/or signs/symptoms of digoxin toxicity (commonly gastrointestinal distress, weakness, dizziness, but in some cases arrhythmia as well) during or shortly after courses of treatment with erythromycin or clarithromycin.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Most patients in these cases were over 70 years old, and several likely had an elevated risk of digoxin toxicity due to additional factors such as renal impairment or hypokalemia. Case reports have also described similar effects in patients receiving digoxin with telithromycin or azithromycin,<sup>18,19</sup> and digitoxin with azithromycin.<sup>20</sup><br><br>Almost all clinical investigations into the interaction between macrolides and cardiac glycosides have involved clarithromycin administration with digoxin. In an observational study of 7 patients 69-90 years old receiving oral digoxin, concomitant treatment with clarithromycin was consistently associated with increased digoxin serum concentrations after 4-7 days.<sup>21</sup> In a prospective study of 8 patients, digoxin pre-dose (trough) serum concentrations were approximately 60% higher on average after 7 days of concomitant clarithromycin.<sup>22</sup> Similarly, the oral digoxin (0.75 mg single dose) maximum concentration and AUC increased by 83% and 64%, respectively, and the non-glomerular digoxin clearance decreased by 40%, in 12 healthy volunteers during clarithromycin coadministration (250 mg orally twice daily, starting the day before digoxin).<sup>23</sup> In contrast to the findings with oral digoxin, in a clinical study of healthy volunteers, coadministration of erythromycin (200 mg orally 4 times daily) or clarithromycin (200 mg orally twice daily) had no impact on intravenous digoxin maximum concentration or AUC, and both were actually associated with 35-40% increases in renal digoxin clearance.<sup>24</sup><br><br>In a clinical study summarized in the telithromycin prescribing information, coadministration of telithromycin with digoxin increased the maximum and trough digoxin concentrations by 73% and 21%, respectively.<sup>25</sup><br><br>Evidence of possible associations between treatment with macrolide antibiotics (clarithromycin, erythromycin, and azithromycin) and hospitalization for digoxin toxicity have been detected in three case control database reviews.<sup>26,27,28</sup> In one of these reviews, clarithromycin was associated with a greater odds of hospitalization for digoxin toxicity than erythromycin or azithromycin.<sup>26</sup><br><br>Several mechanisms have been proposed to explain the interaction between macrolide antibiotics and cardiac glycosides. Macrolide inhibition of P-glycoprotein (P-gp) mediated transport of cardiac glycosides could theoretically lead to increases in glycoside bioavailability and/or decreases in renal clearance. Several macrolides inhibit P-glycoprotein (P-gp) mediated transport of digoxin and digitoxin to some extent in vitro,<sup>29,30,31,32</sup> with telithromycin showing the greatest inhibitory potency, followed by clarithromycin, followed by azithromycin and erythromycin.<sup>29,30</sup> Limited pharmacogenetic data also indicate a modest impact of some variants in the gene coding for P-gp on digoxin bioavailability and renal clearance, but an inconsistent impact of clarithromycin coadministration even among patients carrying similar alleles.<sup>33</sup> A second theory, which has not been the subject of future study with macrolides since its original proposal, is that antibiotics including erythromycin could eradicate gut bacteria capable of metabolizing digoxin, such as <i>Eubacterium lentum</i>, thus leaving greater quantities of unmetabolized drug available for absorption.<sup>34</sup> Finally, a number of additional mechanisms could contribute to this interaction depending on the specific drugs involved. For example, erythromycin, clarithromycin, and telithromycin could elevate digitoxin concentrations via inhibition of its CYP3A mediated metabolism. Erythromycin could also alter the absorption profile of digoxin or digitoxin by increasing the gastric emptying rate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Midoneck SR and Etingin OR, “Clarithromycin-Related Toxic Effects of Digoxin,” <i>N Engl J Med</i>, 1995, 333(22):1505. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7477159\">[PubMed 7477159]</a></p>\n<p>2. Ford A, Smith L, Baltch AL, et al, “Clarithromycin-Induced Digoxin Toxicity in a Patient With AIDS,” <i>Clin Infect Dis</i>, 1995, 21(4):1051-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8645810\">[PubMed 8645810]</a></p>\n<p>3. Brown BA, Wallace RJ Jr, Griffith DE, et al, “Clarithromycin-Associated Digoxin Toxicity in the Elderly,” <i>Clin Infect Dis</i>, 1997, 24(1):92-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8994761\">[PubMed 8994761]</a></p>\n<p>4. Guerriero SE, Ehrenpreis E, and Gallagher KL, “Two Cases of Clarithromycin-Induced Digoxin Toxicity,” <i>Pharmacotherapy</i>, 1997, 17(5):1035-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9324195\">[PubMed 9324195]</a></p>\n<p>5. Laberge P and Martineau P, “Clarithromycin-Induced Digoxin Intoxication,” <i>Ann Pharmacother</i>, 1997, 31(9):999-1002. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9296239\">[PubMed 9296239]</a></p>\n<p>6. Trivedi S, Hyman J, and Lichstein E, “Clarithromycin and Digoxin Toxicity,” <i>Ann Intern Med</i>, 1998, 128(7):604. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9518419\">[PubMed 9518419]</a></p>\n<p>7. Nawarskas JJ, McCarthy DM, and Spinler SA, “Digoxin Toxicity Secondary to Clarithromycin Therapy,” <i>Ann Pharmacother</i>, 1997, 31(7-8):864-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220047\">[PubMed 9220047]</a></p>\n<p>8. Friedman HS and Bonventre MV, “Erythromycin-Induced Digoxin Toxicity,” <i>Chest</i>, 1982, 82(2):202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7094655\">[PubMed 7094655]</a></p>\n<p>9. Maxwell DL, Gilmour-White SK and Hall MR, “Digoxin Toxicity due to Interaction of Digoxin With Erythromycin,” <i>BMJ</i>, 1989, 298(6673):572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2495120\">[PubMed 2495120]</a></p>\n<p>10. Morton MR and Cooper JW, “Erythromycin-Induced Digoxin Toxicity,” <i>DICP</i>, 1989, 23(9):668-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2800579\">[PubMed 2800579]</a></p>\n<p>11. Nordt SP, Williams SR, Manoguerra AS, et al, “Clarithromycin Induced Digoxin Toxicity,” <i>J Accid Emerg Med</i>, 1998, 15(3):194-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9639187\">[PubMed 9639187]</a></p>\n<p>12. Gooderham MJ, Bolli P and Fernandez PG, “Concomitant Digoxin Toxicity and Warfarin Interaction in a Patient Receiving Clarithromycin,” <i>Ann Pharmacother</i>, 1999, 33(7-8):796-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10466907\">[PubMed 10466907]</a></p>\n<p>13. Xu H and Rashkow A, “Clarithromycin-Induced Digoxin Toxicity: A Case Report and a Review of the Literature,” <i>Conn Med</i>, 2001, 65(9):527-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11678058\">[PubMed 11678058]</a></p>\n<p>14. Kiran N, Azam S and Dhakam S, “Clarithromycin Induced Digoxin Toxicity: Case Report and Review,” <i>J Pak Med Assoc</i>, 2004, 54(8):440-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15461217\">[PubMed 15461217]</a></p>\n<p>15. Lee CY, Marcotte F, Giraldeau G, et al, “Digoxin Toxicity Precipitated by Clarithromycin Use: Case Presentation and Concise Review of the Literature,” <i>Can J Cardiol</i>, 2011, 27(6):870.e15-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21907534\">[PubMed 21907534]</a></p>\n<p>16. Hirata S, Izumi S, Furukubo T, et al, “Interactions Between Clarithromycin and Digoxin in Patients With End-Stage Renal Disease,” <i>Int J Clin Pharmacol Ther</i>, 2005, 43(1):30-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15704612\">[PubMed 15704612]</a></p>\n<p>17. Norregaard-Hansen K, Klitgaard NA, and Pedersen KE, “The Significance of the Enterohepatic Circulation on the Metabolism of Digoxin in Patients With the Ability of Intestinal Conversion of the Drug,” <i>Acta Med Scand</i>, 1986, 220(1):89-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3706212\">[PubMed 3706212]</a></p>\n<p>18. Nenciu LM, Laberge P, and Thirion DJG, “Telithromycin-Induced Digoxin Toxicity and Electrocardiographic Changes,” <i>Pharmacother</i>, 2006, 26(6):872-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16716140\">[PubMed 16716140]</a></p>\n<p>19. Ten Eick AP, Sallee D, Preminger T, et al, “Possible Drug Interaction Between Digoxin and Azithromycin in a Young Child,” <i>Clin Drug Invest</i>, 2000, 20:61-4.</p>\n<p>20. Thalhammer F, Hollenstein UM, Locker GJ, et al, “Azithromycin-Related Toxic Effects of Digitoxin,” <i>Br J Clin Pharmacol</i>, 1998, 45(1):91-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9484601\">[PubMed 9484601]</a></p>\n<p>21. Zapater P, Reus S, Tello A, et al, “A Prospective Study of the Clarithromycin-Digoxin Interaction in Elderly Patients,” <i>J Antimicrob Chemother</i>, 2002, 50(4):601-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12356809\">[PubMed 12356809]</a></p>\n<p>22. Tanaka H, Matsumoto K, Ueno K, et al, “Effect of Clarithromycin on Steady-State Digoxin Concentrations,” <i>Ann Pharmacother</i>, 2003, 37(2):178-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12549942\">[PubMed 12549942]</a></p>\n<p>23. Rengelshausen J, Goggelmann C, Burhenne J, et al, “Contribution of Increased Oral Bioavailability and Reduced Nonglomerular Renal Clearance of Digoxin to the Digoxin-Clarithromycin Interaction,” <i>Br J Clin Pharmacol</i>, 2003, 56(1):32-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12848773\">[PubMed 12848773]</a></p>\n<p>24. Tsutsumi K, Kotegawa T, Kuranari M, et al, “The Effect of Erythromycin and Clarithromycin on the Pharmacokinetics of Intravenous Digoxin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(10):1159-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12362931\">[PubMed 12362931]</a></p>\n<p>25. Prescribing information. Ketek (telithromycin). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 12/2010.</p>\n<p>26. Gomes T, Mamdani MM and Juurlink DN, “Macrolide-Induced Digoxin Toxicity: A Population-Based Study,” <i>Clin Pharmacol Ther</i>, 2009, 86(4):383-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19606089\">[PubMed 19606089]</a></p>\n<p>27. Chan AL, Wang MT, Su CY, et al, “Risk of Digoxin Intoxication Caused by Clarithromycin-Digoxin Interactions in Heart Failure Patients: A Population-Based Study,” <i>Eur J Clin Pharmacol</i>, 2009, 65(12):1237-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19655133\">[PubMed 19655133]</a></p>\n<p>28. Juurlink DN, Mamdani M, Kopp A, et al, “Drug-drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity,” <i>JAMA</i>, 2003, 289(13):1652-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12672733\">[PubMed 12672733]</a></p>\n<p>29. Eberl S, Renner B, Neubert A, et al, “Role of P-Glycoprotein Inhibition for Drug Interactions: Evidence From In Vitro and Pharmacoepidemiological Studies,” <i>Clin Pharmacokinet</i>, 2007, 46(12):1039-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18027988\">[PubMed 18027988]</a></p>\n<p>30. Hughes J and Crowe A, “Inhibition of P-Glycoprotein-Mediated Efflux of Digoxin and its Metabolites by Macrolide Antibiotics,” <i>J Pharmacol Sci</i>, 2010, 113(4):315-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20724802\">[PubMed 20724802]</a></p>\n<p>31. Kim RB, Wandel C, Leake B, et al, “Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein,” <i>Pharm Res</i>, 1999, 16(3):408-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10213372\">[PubMed 10213372]</a></p>\n<p>32. Wakasugi H, Yano I, Ito T, et al, “Effect of Clarithromycin on Renal Excretion of Digoxin: Interaction With P-Glycoprotein,” <i>Clin Pharmacol Ther</i>, 1998, 64(1):123-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9695727\">[PubMed 9695727]</a></p>\n<p>33. Kurata Y, Ieiri I, Kimura M, et al, “Role of Human MDR1 Gene Polymorphism in Bioavailability and Interaction of Digoxin, a Substrate of P-Glycoprotein,” <i>Clin Pharmacol Ther</i>, 2002, 72(2):209-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12189368\">[PubMed 12189368]</a></p>\n<p>34. Lindenbaum J, Rund DG, Butler VP Jr, et al, “Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy,” <i>N Engl J Med</i>, 1981, 305(14):789-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7266632\">[PubMed 7266632]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3055":"<p><b>Title</b> Cardiac Glycosides / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased cardiac glycoside toxicity (eg, cardiac arrhythmias) if a loop diuretic is initiated or the dose is increased. Careful monitoring of serum potassium and magnesium along with administration of electrolyte replacement therapy to correct hypokalemia or hypomagnesemia may reduce the risk of cardiac glycoside toxicity.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The risk of cardiac glycoside toxicity increases in the presence hypokalemia and hypomagnesemia, even when serum concentrations are maintained in the therapeutic range.<sup>1</sup> The association of digitalis toxicity and electrolyte disturbances induced by diuretic (loop and thiazide) use has been reported in numerous studies<sup>2,3,4,5,6,7,8</sup> and case reports<sup>9,10</sup> In contrast, some studies report that serum potassium levels do not influence the risk of digitalis toxicity,<sup>11,12,13</sup> possibly because serum potassium concentrations may not correlate with total body potassium stores.<br><br>Prescribing information for digoxin recommends careful monitoring of serum potassium and magnesium levels in patients receiving digoxin along with diuretics.<sup>1</sup> Administering electrolyte replacement to correct hypokalemia and hypomagnesemia is recommended.<br><br>Cardiac glycosides and potassium compete for binding to the cardiac sodium-potassium ATP pump (Na-K-ATPase). It is proposed that in the presence of hypokalemia, the reduced competition for the Na-K-ATPase allows for more cardiac glycoside binding and effects. Further binding of the glycoside to the Na-K-ATPase reduces intracellular potassium, which is thought to increase the risk of cardiac glycoside toxicity.<sup>14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digoxin [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2012.</p>\n<p>2. Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalemia and potassium loss during maintenance digoxin therapy. <i>Br Heart J</i>. 1976;38(2):167-172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1259829\">[PubMed 1259829]</a></p>\n<p>3. Jorgensen AW, Sorensen OH. Digitalis intoxication. A comparative study on the incidence of digitalis intoxication during the periods 1950-52 and 1964-66. <i>Acta Med Scand</i>. 1970;188(3):179-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5526940\">[PubMed 5526940]</a></p>\n<p>4. Rodensky PL, Wasserman F. Observations on digitalis intoxication. <i>Arch Intern Med</i>. 1961;108:171-188. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13742523\">[PubMed 13742523]</a></p>\n<p>5. Beller GA, Hood WB Jr, Smith TW, Abelmann WH, Wacker WE. Correlation of serum magnesium levels and cardiac digitalis intoxication. <i>Am J Cardiol</i>. 1974;33(2):225-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4810019\">[PubMed 4810019]</a></p>\n<p>6. Sundar S, Burma DP, Vaish SK. Digoxin toxicity and electrolytes: a correlative study. <i>Acta Cardiol</i>. 1983;38(2):115-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6603084\">[PubMed 6603084]</a></p>\n<p>7. Shapiro S, Slone D, Lewis GP, Jick H. The epidemiology of digoxin. A study in three Boston hospitals. <i>J Chronic Dis</i>. 1969;22(5):361-371. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5352781\">[PubMed 5352781]</a></p>\n<p>8. Wang MT, Su CY, Chan AL, Lian PW, Leu HB, Hsu YJ. Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study. <i>Br J Clin Pharmacol</i>. 2010;70(2):258-267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653679\">[PubMed 20653679]</a></p>\n<p>9. Raja Rao MP, Panduranga P, Sulaiman K, Al-Jufaili M. Digoxin toxicity with normal digoxin and serum potassium levels: beware of magnesium, the hidden malefactor. <i>J Emerg Med</i>. 2013;45(2):e31-e34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23685098\">[PubMed 23685098]</a></p>\n<p>10. Gomez-Arnau J, Maseda J, Burgos R, et al. Cardiac arrest due to digitalis intoxication with normal serum digoxin levels: effects of hypokalemia. <i>Drug Intell Clin Pharm</i>. 1982;16(2):160-161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7075468\">[PubMed 7075468]</a></p>\n<p>11. Ogilvie RI, Ruedy J. An educational program in digitalis therapy. <i>JAMA</i>. 1972;222(1):50-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5068673\">[PubMed 5068673]</a></p>\n<p>12. Beller GA, Smith TW, Abelmann WH, Haber E, Hood WB Jr. Digitalis intoxication. A prospective clinical study with serum level correlations. <i>N Engl J Med</i>. 1971;284(18):989-997. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5553483\">[PubMed 5553483]</a></p>\n<p>13. Myers MG. Diuretic therapy and ventricular arrhythmias in persons 65 years of age and older. <i>Am J Cardiol</i>. 1990;65(9):599-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1689934\">[PubMed 1689934]</a></p>\n<p>14. Brater DC, Morrelli HF. Digoxin toxicity in patients with normokalemic potassium depletion. <i>Clin Pharmacol Ther</i>. 1977;22(1):21-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=872493\">[PubMed 872493]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3056":"<p><b>Title</b> Cardiac Glycosides / Kaolin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of cardiac glycosides are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Kaolin may decrease the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cardiac glycosides if kaolin is initiated/dose increased, or increased serum concentrations/effects if kaolin is discontinued/dose decreased. In response to changes in serum glycoside concentrations (or a priori to reduce the risk of interaction), the patient may be instructed to separate doses of the glycoside and kaolin by at least 2 hours.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of digoxin was decreased 15% in 7 patients when administered concurrently with kaolin-pectin.<sup>1</sup> When doses of digoxin and kaolin-pectin were separated by 2 hours, no changes in digoxin pharmacokinetics were seen. Single dose studies have noted more significant reductions in digoxin bioavailability (42% and 62%).<sup>2,3</sup> Another noted that no effect was evident between digoxin capsules and kaolin.<sup>4</sup> The clinical significance of this interactions would seem quite small, nonetheless, separating doses could virtually eliminate all risk. The mechanism of this interaction is unknown. Kaolin appears to inhibit digoxin absorption, possibly by binding to the drug within the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Albert KS, Elliott WJ, Abbott RD, et al, “Influence of Kaolin-Pectin on Steady-State Digoxin Levels,” <i>J Clin Pharmacol</i>, 1981, 21:449-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7309406\">[PubMed 7309406]</a></p>\n<p>2. Brown DD, Juhl RP, Lewis K, et al, “Decreased Bioavailability of Digoxin Due to Antacids and Kaolin-Pectin,” <i>N Engl J Med</i>, 1976, 295:1034. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=972657\">[PubMed 972657]</a></p>\n<p>3. Albert KS, Ayres JW, Disanto AR, et al, “Influence of Kaolin-Pectin Suspension on Digoxin Bioavailability,” <i>J Pharm Sci</i>, 1978, 67:1582. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=712546\">[PubMed 712546]</a></p>\n<p>4. Allen MD, Greenblatt DJ, Harmatz JS, et al, “Effect of Magnesium Aluminum Hydroxide and Kaolin-Pectin on Absorption of Digoxin From Tablets and Capsules,” <i>J Clin Pharmacol</i>, 1981, 21:26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7012189\">[PubMed 7012189]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3058":"<p><b>Title</b> Cardiac Glycosides / Aminoglycosides</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with oral administration of both agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cardiac glycosides if an oral aminoglycoside antibiotic is initiated/dose increased, or increased effects if an oral aminoglycoside antibiotic is discontinued/dose decreased. Dose spacing does not appear to help minimize this interaction. Intravenous digoxin administration will bypass this interaction.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Arbekacin, Gentamicin (Systemic), Isepamicin, Neomycin*<br><b>Exceptions</b> Amikacin, Kanamycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, the steady state AUC of digoxin was reduced an average of 28% when administered concurrently with oral neomycin.<sup>1</sup> The interaction was evident even if the neomycin was administered as many as 6 hours before the digoxin. <br><br>In a second study, systemic gentamicin (80 mg intramuscular twice daily) was associated with a significant increase in serum creatinine and digoxin concentration in patients with congestive heart failure.<sup>2</sup> However, due to methodologic and reporting deficiencies this study provides only very weak evidence of an interaction between gentamicin and digoxin.<br> <br>The mechanism by which oral aminoglycosides may decrease digoxin exposure is unknown. In vitro studies indicated that neomycin did not precipitate digoxin in bile or intestinal fluids and did not interfere with digoxin movement across dialysis membranes.<sup>1</sup> Increases in digoxin concentration seen with gentamicin coadministration were likely an indirect consequence of gentamicin induced renal toxicity rather than a true interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lindenbaum J, Maulitz RM, and Butler V, “Inhibition of Digoxin Absorption by Neomycin,” <i>Gastroenterology</i>, 1976, 71:399-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=950089\">[PubMed 950089]</a></p>\n<p>2. Alkadi HO, Nooman MA and Raja'a YA, “Effect of Gentamicin on Serum Digoxin Level in Patients With Congestive Heart Failure,” <i>Pharm World Sci</i>, 2004, 26(2):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15085946\">[PubMed 15085946]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3059":"<p><b>Title</b> Cardiac Glycosides / Propafenone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propafenone may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cardiac glycosides if propafenone is initiated/dose increased, or decreased serum concentrations/effects if propafenone is discontinued/dose decreased.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Five patients receiving digoxin who were given propafenone (900 mg/day) as part of a clinical trial experienced an average 83% increase in trough digoxin concentrations by day 3 of concomitant treatment.<sup>1</sup> Three children given propafenone while receiving digoxin experienced greater, 170% increases in digoxin concentration following addition of propafenone (250 - 500 mg/m2/day, some may have received loading doses).<sup>2</sup> In pharmacokinetic studies in adults, propafenone has caused dose-related increases in serum digoxin concentrations, ranging from roughly 35% at 450mg/day to 85% at 900 mg/day of propafenone.<sup>3,4,5</sup><br><br>The mechanism of interaction between digoxin and propafenone has not been established. One possible mechanism is inhibition of P-glycoprotein mediated renal tubular digoxin transport by propafenone and/or its metabolites.<sup>6,7</sup> However, one study in healthy volunteers showed no significant change in renal clearance of digoxin with propafenone treatment.<sup>8</sup> There was a nonsignificant trend toward decreased digoxin volume of distribution and increased nonrenal clearance with propafenone, which could provide an alternative explanation. There are no data validating an interaction between digitoxin and propafenone in humans, but similar caution may be warranted based on a study in rabbits indicating increases in digitoxin serum concentrations with propafenone.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Salerno DM, Granrud G, Sharkey P, et al, “A Controlled Trial of Propafenone for Treatment of Frequent and Repetitive Ventricular Premature Complexes,” <i>Am J Cardiol</i>, 1984, 53:77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6362387\">[PubMed 6362387]</a></p>\n<p>2. Zalzstein E, Koren G, Bryson SM, et al, “Interaction Between Digoxin and Propafenone in Children,” <i>J Pediatr</i>, 1990, 116(2):310-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2299507\">[PubMed 2299507]</a></p>\n<p>3. Calvo MV, Martin-Suarez A, Luengo CM, et al, “Interaction Between Digoxin and Propafenone,” <i>Ther Drug Monit</i>, 1989, 11:10-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2911842\">[PubMed 2911842]</a></p>\n<p>4. Belz GG, Doering W, Munkes R, et al, “Interaction Between Digoxin and Calcium Antagonists and Antiarrhythmic Drugs,” <i>Clin Pharmacol Ther</i>, 1983, 33:410-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6831819\">[PubMed 6831819]</a></p>\n<p>5. Prescribing Information.Propafenone. St. Louis, MO: Ethex Corporation, 3/2007.</p>\n<p>6. Woodland C, Verjjee Z, Giesbrecht E, et al,“The Digoxin-Propafenone Interaction: Characterization of a Mechanism Using Renal Tubular Monolayers,” <i>J Pharmacol ExpTher</i>, 1997, 283:39-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9336306\">[PubMed 9336306]</a></p>\n<p>7. Bachmakov I, Rekersbrink S, Hofmann U, et al, “Characterisation of (R/S)-Propafenone and its Metabolites as Substrates and Inhibitors of P-Glycoprotein,” <i>Naunyn Schmiedebergs Arch Pharmacol</i>, 2005, 371(3):195-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15900513\">[PubMed 15900513]</a></p>\n<p>8. Nolan PE, Marcus Fl, Erstad BL, et al, “Effects of Coadministration of Propafenone on the Pharmacokinetics of Digoxin in Healthy Volunteer Subjects,” <i>J Clin Pharmacol</i>, 1989, 29:46-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2708548\">[PubMed 2708548]</a></p>\n<p>9. Sphakianaki E, Tsouderos I, Morali A, et al, “Interactions Between Digitoxin and Some Antiarrhythmic Drugs,” <i>Methods Find Exp Clin Pharmacol</i>, 92, 14(5):355-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1513190\">[PubMed 1513190]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3060":"<p><b>Title</b> Cardiac Glycosides / QuiNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> QuiNIDine may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until quinidine reaches steady state (5-10 days). Monitor for toxic effects of cardiac glycosides if quinidine is initiated or the dose is increased.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin*, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The addition of quinidine to a stable digoxin regimen will likely result in a 100% increase in serum digoxin concentrations in at least 9 of 10 patients.<sup>1,2,3,4,5,6,7</sup> Digitoxin appears to be similarly affected.<sup>8,9</sup> <br><br>Multiple mechanisms may contribute to this interaction. Quinidine inhibition of p-glycoprotein mediated glycoside transport appears to enhance systemic absorption of digoxin<sup>10</sup> and may decrease its elimination. Additionally, increased digoxin concentrations may saturate skeletal muscle binding sites, increasing the proportion in circulation.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Leahey EB, Reiffel JA, Drusin RE, et al, “Interaction Between Quinidine and Digoxin,” <i>JAMA</i>, 1978, 240(6):533-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=671662\">[PubMed 671662]</a></p>\n<p>2. Ejvinsson G, “Effect of Quinidine on Plasma Concentrations of Digoxin,” <i>Br Med J</i>, 1978, 1(6108):279-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=620306\">[PubMed 620306]</a></p>\n<p>3. Angelin B, Arvidsson A, Dahlquist R, et al, “Quinidine Reduces Biliary Clearance of Digoxin in Man,” <i>Eur J Clin Invest</i>, 1987, 17(3):262-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3113970\">[PubMed 3113970]</a></p>\n<p>4. Mungall DR, Robichaux RP, Perry W, et al, “Effects of Quinidine on Serum Digoxin Concentration,” <i>Ann Intern Med</i>, 1980, 93(5):689-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7212476\">[PubMed 7212476]</a></p>\n<p>5. Ochs HR, Bodem G, and Greenblatt DJ, “Impairment of Digoxin Clearance by Coadministration of Quinidine,” <i>J Clin Pharmacol</i>, 1981, 21(10):396-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7309901\">[PubMed 7309901]</a></p>\n<p>6. Williams JF Jr and Mathew B, “Effect of Quinidine on Positive Inotropic Action of Digoxin,” <i>Am J Cardiol</i>, 1981, 47(5):1052-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7223650\">[PubMed 7223650]</a></p>\n<p>7. Leahey EB Jr, Bigger JT Jr, Butler VP Jr, et al, “Quinidine-Digoxin Interaction: Time Course and Pharmacokinetics,” <i>Am J Cardiol</i>, 1981, 48(6):1141-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7304462\">[PubMed 7304462]</a></p>\n<p>8. Garty M, Sood P, and Rollins DE, “Digitoxin Elimination Reduced During Quinidine Therapy,” <i>Ann Intern Med</i>, 1981, 94(1):35-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7447220\">[PubMed 7447220]</a></p>\n<p>9. Kuhlmann J, Dohrmann M, and Marcin S, “Effects of Quinidine on Pharmacokinetics and Pharmacodynamics of Digitoxin Achieving Steady-State Conditions,” <i>Clin Pharmacol Ther</i>, 1986, 39(3):288-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3512148\">[PubMed 3512148]</a></p>\n<p>10. Igel S, Drescher S, Murdter T, et al, “Increased Absorption of Digoxin From the Human Jejunum due to Inhibition of Intestinal Transporter-Mediated Efflux,” <i>Clin Pharmacokinet</i>, 2007, 46(9):777-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17713975\">[PubMed 17713975]</a></p>\n<p>11. Jogestrand T, Schenck-Gustafsson K, Nordlander R, et al, “Quinidine-Induced Changes in Serum and Skeletal Muscle Digoxin Concentration; Evidence of Saturable Binding of Digoxin to Skeletal Muscle,” <i>Eur J Clin Pharmacol</i>, 1984, 27(5):571-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6519162\">[PubMed 6519162]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3063":"<p><b>Title</b> Cardiac Glycosides / Neuromuscular-Blocking Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> Monitor for the development of cardiac arrhythmias when neuromuscular blocking agents are administered to patients who are receiving cardiac glycosides.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium*, Rocuronium, Succinylcholine*, Vecuronium</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serious cardiac arrhythmias have developed in digoxin-stable patients following the administration of succinylcholine or pancuronium.<sup>1,2,3,4</sup> <br><br>The mechanism of this possible interaction is unclear. Succinylcholine (a depolarizing neuromuscular blocking agent - NMB) has been implicated in the majority of cases and has been associated with extracellular shifts of myocardial potassium stores.<sup>5</sup> The potential for nondepolarizing NMBs (other than pancuronium) to cause arrhythmias is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dowdy EG and Fabian LW, “Ventricular Arrhythmias Induced by Succinylcholine in Digitalized Patients. A Preliminary Report,” <i>Anesth Analg</i>, 1963, 42:501.</p>\n<p>2. Perez HR, “Cardiac Arrhythmia After Succinylcholine,” <i>Anesth Analg</i>, 1970, 49:33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5461068\">[PubMed 5461068]</a></p>\n<p>3. Smith RB and Petrusack J, “Succinylcholine, Digitalis and Hypercalcaemia; A Case Report,” <i>Anesth Analg</i>, 1972, 51:202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5062119\">[PubMed 5062119]</a></p>\n<p>4. Bartolone RS and Rao TLK, “Dysrhythmia Following Muscle Relaxant Administration in Patients Receiving Digitalis,” <i>Anesthesiology</i>, 1983, 58:567. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6222678\">[PubMed 6222678]</a></p>\n<p>5. Birch AA, Jr, Mitchell GD, Playford GA, et al, “Changes in Serum Potassium Response to Succinylcholine Following Trauma,” <i>JAMA</i>, 1969, 210:490. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5394378\">[PubMed 5394378]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3064":"<p><b>Title</b> Cardiac Glycosides / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Tetracyclines may increase the absorption of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of cardiac glycosides if an oral tetracycline antibiotic is initiated/dose increased, or decreased effects if an oral tetracycline antibiotic is discontinued/dose decreased. Dose spacing does not appear to help minimize this interaction. Administering IV formulations of digoxin will bypass this interaction.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. Steady state serum digoxin concentrations increased approximately 30% in a patient following 5 days of oral tetracycline therapy (500 mg every 6 hours).<sup>1</sup> Tetracycline likely reduces gut flora that would otherwise metabolize some digoxin prior to absorption in some patients. Only oral administration of the antibiotic and cardiac glycoside are of concern.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lindenbaum J, Rund DG, Butler VP, et al, “Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy,” <i>N Engl J Med</i>, 1981, 305:789-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7266632\">[PubMed 7266632]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3066":"<p><b>Title</b> Calcium Channel Blockers / Rifamycin Derivatives</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Clinical action rating appears dependent on specific product used. This combination is contraindicated or not recommended in some but not all calcium channel blocker labeling, and in some it is not listed or discussed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> The US labeling for at least one specific brand of nifedipine (Adalat CC) contraindicates concurrent use with rifampin. The Canadian labeling for extended release nifedipine (Adalat XL, Mylan-Nifedipine) and for nimodipine contraindicates concurrent use with rifampin. Consider alternative therapy to these contraindicated agents in patients receiving rifampin. Other calcium channel blockers (CCBs) will likely interact with rifamycin derivatives to at least some degree. If using this combination, monitor patients closely for clinical signs of diminished CCB therapeutic effects. CCB dose increases or alternative (non-CCB) therapy may be necessary.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine*, NiMODipine, Nisoldipine, Nitrendipine, Verapamil*<br><b>Exception</b> Clevidipine</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to data in nifedipine prescribing information, the mean nifedipine AUC and maximum serum concentration (Cmax) were reduced by 97% and 95%, respectively, when nifedipine (20 mg single dose) was given after 14 days of pretreatment with rifampin (600 mg/day) in a study of 12 healthy volunteers.<sup>1</sup> These findings are consistent with those of published studies that have reported several-fold increases in nifedipine clearance and substantially reduced nifedipine bioavailability when nifedipine was coadministered with rifampin in healthy volunteers.<sup>2,3</sup> Loss of nifedipine efficacy in the presence of rifampin has been reported.<sup>4,5</sup> Relatively similar effects on nifedipine concentrations have been observed with other drugs that are inducers of CYP3A, with concurrent phenytoin associated with an approximate 70% decrease in nifedipine AUC and concurrent St John's wort associated with a 29% to 48% decrease in nifedipine AUC.<sup>1,6</sup> The Cmax and AUC of nilvadipine (4 mg single dose) decreased 95% and 96%, respectively, in the presence of rifampin (450 mg daily for 6 days).<sup>7</sup> Similar pharmacokinetic effects, accompanied by loss of drug efficacy, have been reported with rifampin combined with verapamil.<sup>8,9,10</sup><br><br>The mechanism of these interactions is likely related to the ability of rifampin to induce CYP3A4, especially in the intestinal mucosa, thus increasing calcium channel blocker metabolism and decreasing absorption. Data from one study that evaluated both oral and intravenous nifedipine support the key role of intestinal CYP3A4 in this interaction, finding little evidence for a substantial change in the hepatic extraction of nifedipine (but a large increase for gut wall extraction) and only a small impact on the pharmacokinetics of intravenous nifedipine.<sup>3</sup> In terms of potency/risk of CYP3A4 induction rifampin &gt; rifapentine &gt; rifabutin. <br><br>In the US and Canada, manufacturer labeling recommendations regarding use of calcium channel blockers with rifamycins vary. In the US, at least one nifedipine product (Adalat CC) lists concurrent use of strong CYP3A4 inducers such as rifampin as a contraindication<sup>11</sup>; however, not all US oral nifedipine products list this combination as a contraindication.<sup>12</sup> In Canada, concomitant use of rifampin with extended-release nifedipine (Adalat XL, Mylan-Nifedipine) and nimodipine is contraindicated.<sup>13,14,15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adalat</i> (nifedipine) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2008.</p>\n<p>2. Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single dose of rifampicin on the pharmacokinetics of oral nifedipine. <i>J Pharm Biomed Anal</i>. 1997;15(9-10):1571-1575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9226591\">[PubMed 9226591]</a></p>\n<p>3. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. <i>Drug Metab Dispos</i>. 1996;24(10):1121-1123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8894514\">[PubMed 8894514]</a></p>\n<p>4. Tsuchihashi K, Fukami K, Kishimoto H, et al. A case of variant angina exacerbated by administration of rifampicin. <i>Heart Vessels</i>. 1987;3(4):214-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3453828\">[PubMed 3453828]</a></p>\n<p>5. Tada Y, Tsuda Y, Otsuka T, et al. Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. <i>Am J Med Sci</i>. 1992;303(1):25-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1345893\">[PubMed 1345893]</a></p>\n<p>6. Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. <i>Br J Clin Pharmacol</i>. 2009;67(2):255-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19173680\">[PubMed 19173680]</a></p>\n<p>7. Saima S, Furuie K, Yoshimoto H, Fukuda J, Hayashi T, Echizen H. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. <i>Br J Clin Pharmacol</i>. 2002;53(2):203-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11851646\">[PubMed 11851646]</a></p>\n<p>8. Rahn KH, Mooy K, Bohm R, vd Vet A. Reduction of bioavailability of verapamil by rifampin. <i>N Eng J Med</i>. 1985;312(14):920-921. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3974676\">[PubMed 3974676]</a></p>\n<p>9. Barbarash RA. Verapamil-rifampin interaction. <i>Drug Intell Clin Pharm</i>. 1985;19(7-8):559-560. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4028962\">[PubMed 4028962]</a></p>\n<p>10. Mooy J, Bohm R, van Baak M, van Kemenade J, vd Vet A, Rahn KH. The influence of antituberculosis drugs on the plasma level of verapamil. <i>Eur J Clin Pharmacol</i>. 1987;32(1):107-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3582463\">[PubMed 3582463]</a></p>\n<p>11. <i>Adalat CC</i> (nifedipine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2010.</p>\n<p>12. <i>Procardia XL</i> (nifedipine) [prescribing information]. New York, NY: Pfizer Labs; May 2014. </p>\n<p>13. <i>Adalat XL</i> (nifedipine) [product monograph]. Toronto, Ontario: Bayer Inc; November 2010.</p>\n<p>14. <i>Mylan-Nifedipine Extended Release</i> (nifedipine) [product monograph]. Etobicoke, Ontario: Mylan Pharmaceuticals ULC; April 2010.</p>\n<p>15. <i>Nimotop</i> (nimodipine) [product monograph]. Toronto, Ontario: Bayer Inc; April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3068":"<p><b>Title</b> Corticosteroids (Systemic) / Progestins</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Progestins may increase the serum concentration of Corticosteroids (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> The effects of hormonal contraceptives on corticosteroid disposition is likely more related to estrogen that progestin content. However, since such cannot be known with certainty, monitor for increased therapeutic or toxic effects of corticosteroids if a progestin is initiated/dose increased, or decreased effects if a progestin is discontinued/dose decreased. These effects are probably of little consequence in patients receiving nonsystemic corticosteroid therapy (eg, topical, inhalation).</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Progestins Interacting Members</b> Chlormadinone, Cyproterone, Desogestrel, Dienogest, Drospirenone, Dydrogesterone, Ethynodiol Diacetate, Etonogestrel, Gestodene, HYDROXYprogesterone Caproate, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Megestrol, Norelgestromin, Norethindrone, Norgestimate, Norgestrel, Progesterone*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of a single dose of prednisolone was increased by approximately sixfold in 6 women taking oral contraceptives (clearance was decreased).<sup>1</sup> Similar results were reported in a study comparing the clearance and AUC of prednisolone in both male (n=8) and female (n=13) subjects. Eight of the female subjects were receiving oral contraceptives. The oral contraceptive group demonstrated an approximate 50% reduction in steroid clearance and 100% in steroid AUC.<sup>2</sup> Other reports support these results in patients receiving prednisolone, and methylprednisolone.<sup>3,4,5,6</sup> In contrast, the pharmacokinetics of prednisolone was not significantly affected in women when administered following a 2-month course of progesterone.<sup>7</sup> This may suggest that the effects seen with oral contraceptives is due to the estrogen component, and not the progestin. The mechanism of these interactions is not firmly established, but may be related to an estrogen-induced change in: 1) steroid metabolism; or 2) the ability of the steroid to bind to serum proteins. Caution may be warranted with progestin-only regimens. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Legler UF and Benet LZ, “Marked Alterations in Prednisolone Elimination for Women Taking Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1982, 31:243.</p>\n<p>2. Boekenoogen SJ, Szefler SJ, and Jusko WJ, “Prednisolone Disposition and Protein Binding in Oral Contraceptive Users,” <i>J Clin Endocrinol Metab</i>, 1983, 56:702-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6833459\">[PubMed 6833459]</a></p>\n<p>3. Legler UF and Benet LZ, “Marked Alterations in Dose-Dependent Prednisolone Kinetics in Women Taking Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1986, 39:425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3956058\">[PubMed 3956058]</a></p>\n<p>4. Frey BM, Schaad HJ, and Frey FJ, “Pharmacokinetic Interaction of Contraceptive Steroids With Prednisone and Prednisolone,” <i>Eur J Clin Pharmacol</i>, 1984, 26:505-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734709\">[PubMed 6734709]</a></p>\n<p>5. Meffin PJ, Wing LM, Sallustio BC, et al, “Alterations in Prednisolone Disposition as a Result of Oral Contraceptive Use and Dose,” <i>Br J Clin Pharmacol</i>, 1984, 17:655-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6743464\">[PubMed 6743464]</a></p>\n<p>6. Slayter KL, Ludwig EA, Lew KH, et al, “Oral Contraceptive Effects on Methylprednisolone Pharmacokinetics and Pharmacodynamics,” <i>Clin Pharmacol Ther</i>, 1996, 59:312-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8653994\">[PubMed 8653994]</a></p>\n<p>7. Tsunoda SM, Harris RZ, Mroczkowski PJ, et al, “Oral Progesterone Therapy Does Not Affect the Pharmacokinetics of Prednisolone and Erythromycin in Postmenopausal Women,” <i>Clin Pharmacol Ther</i>, 1995, 57:182.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3069":"<p><b>Title</b> Corticosteroids (Systemic) / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of salicylates if corticosteroids are initiated/dose increased, or toxic effects if corticosteroids are discontinued/dose decreased. Monitor for gastrointestinal irritation and ulceration. For patients receiving large, chronic doses of salicylates, an a priori dosage reduction could be considered when corticosteroids are being withdrawn.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin*, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone*, PrednisoLONE (Systemic), PredniSONE*, Triamcinolone (Systemic)</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid*, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate*, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe reductions in salicylate serum concentrations to below desired therapeutic levels following the addition of a corticosteroid to a patient's regimen.<sup>1,2</sup> Similar effects were seen in 10 patients given intra-articular corticosteroids.<sup>3,4</sup> Corticosteroid withdrawal in patients receiving salicylates has been associated with 3 to 9 fold increases in salicylate serum concentrations and symptoms of salicylate intoxication.<sup>1,2,5</sup> In contrast to these findings, one study of 6 healthy volunteers showed no apparent impact of pretreatment with prednisone (12-60 mg orally daily) on single-dose sodium salicylate (10 mg/kg orally) clearance.<sup>6</sup> AUC data were not given. <br><br>The mechanism of the observed interactions is unknown. Animal and in vitro data do not indicate a clear pharmacokinetic relation: a study in mice suggested induction of hepatic aspirin esterase and UDP-glucuronyltransferase activity by hydrocortisone;<sup>7</sup> a second study in mice showed an apparent reduction in intestinal aspirin esterase with dexamethasone;<sup>8</sup> a study in rats showed decreased renal clearance and increased hepatic clearance of dexamethasone with aspirin coadministration;<sup>9</sup> and an in vitro study showed no apparent impact of cortisone acetate on serum aspirin esterase activity.<sup>10</sup> In addition to concerns over salicylate concentrations with coadministration, an increased risk of some overlapping toxicities of the individual agents (e.g. gastrointestinal ulceration) is also expected.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Graham GG, Champion GD, Day RO, et al, “Patterns of Plasma Concentrations and Urinary Excretion of Salicylate in Rheumatoid Arthritis,” <i>Clin Pharmacol Ther</i>, 1977, 22:410-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=902454\">[PubMed 902454]</a></p>\n<p>2. Koren G, Roifman C, Gelfand E, et al, “Corticosteroids-Salicylate Interaction in a Case of Juvenile Rheumatoid Arthritis,” <i>Ther Drug Monit</i>, 1987, 9:177-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3617157\">[PubMed 3617157]</a></p>\n<p>3. Edelman J, Potter JM, Hackett LP, et al, “The Effect of Intra-articular Steroids on Plasma Salicylate Concentrations,” <i>Br J Clin Pharmacol</i>, 1986, 21:301-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3485989\">[PubMed 3485989]</a></p>\n<p>4. Baer PA, Shore A, and Ikeman RL, “Transient Fall in Serum Salicylate Levels Following Intra-articular Injection of Steroid in Patients With Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 1987, 30:345-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3566826\">[PubMed 3566826]</a></p>\n<p>5. Klinenberg JR and Miller F, “Effect of Corticosteroids on Blood Salicylate Concentration,” <i>JAMA</i>, 1965, 194:601-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5897233\">[PubMed 5897233]</a></p>\n<p>6. Day RO, Harris G, Brown M, et al, “Interaction of Salicylate and Corticosteroids in Man,” <i>Br J Clin Pharmacol</i>, 1988, 26(3):334-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3179172\">[PubMed 3179172]</a></p>\n<p>7. Tantcheva L, Stoytchev T and Rangelova D, “Influence of Hydrocortisone on the Analgesic Effect, Toxicity and Metabolism of Aspirin in Mice,” <i>Gen Pharmacol</i>, 1997, 28(1):123-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9112088\">[PubMed 9112088]</a></p>\n<p>8. Tantcheva L, Stoytchev T and Rangelova D, “Interaction of Dexamethasone With Acetylsalicylic Acid in Mice,” <i>Methods Find Exp Clin Pharmacol</i>, 1997, 19(6):387-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9385588\">[PubMed 9385588]</a></p>\n<p>9. Kassem MA and Schulte KE, “Influence of Phenylbutazone, Mofebutazone and Aspirin on the Pharmacokinetics of Dexamethasone in the Rat,” <i>Eur J Drug Metab Pharmacokinet</i>, 1981, 6(1):11-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7250148\">[PubMed 7250148]</a></p>\n<p>10. Gupta JD, Gruca M and Ablett W, “Effect of Other Drugs and Chemicals on the Degradation of Aspirin in Vitro: Possible Extrapolation to In Vivo Metabolism of Aspirin,” <i>Eur J Drug Metab Pharmacokinet</i>, 1979, 4(2):103-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=488131\">[PubMed 488131]</a></p>\n<p>11. Carson JL, Strom BL, Schinnar R, et al, “Do Corticosteroids Really Cause Upper GI Bleeding?” <i>Clin Res</i>, 1987, 35:340A.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3071":"<p><b>Title</b> Alfentanil / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Alfentanil. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced alfentanil effectiveness in any patient who is actively receiving or has recently received rifampin (or other rifamycin derivative) within the past several days. Increased alfentanil doses will likely be needed. Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> An average 53% decrease in alfentanil AUC and an approximate 3-fold increase in alfentanil (20 mcg/kg IV) clearance were reported in one study of nine healthy volunteers who were receiving concomitant rifampin (75 mg/day x 5 days).<sup>1</sup> Similarly, in a study using several different rifampin doses, both alfentanil concentrations and alfentanil pharmacodynamics (i.e., miosis) were significantly altered by concurrent rifampin in a dose-dependent manner.<sup>2</sup><br><br>This apparent interaction is is likely due to rifampin's ability to induce the CYP3A4-mediated metabolism of alfentanil. The related rifamycins rifabutin and rifapentine would also be expected to affect alfentanil in a generally similar fashion, though neither agent is as potent of an enzyme inducer as rifampin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kharasch ED, Russell M, Mautz D, et al, “The Role of Cytochrome P450 3A4 in Alfentanil Clearance. Implications for Interindividual Variability in Disposition and Perioperative Drug Interactions,” <i>Anesthesiology</i>, 1997, 87(1):36-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9232132\">[PubMed 9232132]</a></p>\n<p>2. Kharasch ED, Francis A, London, A, et al. “Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimal and Noninvasive Probes for Hepatic and First-Pass CYP3A Induction,” <i>Clin Pharmacol Ther</i>, 2011, 90(1):100-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21562488\">[PubMed 21562488]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3075":"<p><b>Title</b> Disopyramide / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of disopyramide and an interacting macrolide antibiotic should be avoided, if possible. Azithromycin is not likely to cause problems. If disopyramide and an interacting macrolide antibiotic are used concomitantly monitor for development of signs/symptoms of QTc prolongation/ventricular arrhythmias. Macrolide dosage increases should be closely monitored.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin*, Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports have documented the development of life-threatening ventricular arrhythmias in patients who have been receiving disopyramide therapy for multiple years (without incident) within a few days of starting clarithromycin or erythromycin therapy.<sup>1,2</sup> Disopyramide serum concentrations were elevated in these cases. The mechanism of these interactions may be multifold. Both clarithromycin and erythromycin are reported to inhibit CYP3A4, the enzyme responsible for metabolism of disopyramide. <i>In vitro</i> evidence shows that erythromycin inhibits disopyramide metabolism.<sup>3</sup> They also are individually implicated as agents that can prolong QTc intervals. The combined effects could indeed be life-threatening if gone unnoticed. Other macrolides may possess the ability to effect one or both of these problems. Telithromycin, a ketolide antibiotic, likewise is a strong inhibitor of CYP3A4. Azithromycin and spiramycin would not likely interact with disopyramide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Paar D, Terjung B, and Sauerbruch T, “Life-Threatening Interaction Between Clarithromycin and Disopyramide,” <i>Lancet</i>, 1997, 349(9048):326-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9024381\">[PubMed 9024381]</a></p>\n<p>2. Ragosta M, Weihl AC, and Rosenfeld LE, “Potentially Fatal Interaction Between Erythromycin and Disopyramide,” <i>Am J Med</i>, 1989, 86(4):465-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2467560\">[PubMed 2467560]</a></p>\n<p>3. Echizen H, Kawasaki H, Chiba K, et al, “A Potent Inhibitory Effect of Erythromycin and Other Macrolide Antibiotics on the Mono-N-Dealkylation Metabolism of Disopyramide With Human Liver Microsomes,” <i>J Pharmacol Exp Ther</i>, 1993, 264(3):1425-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8450476\">[PubMed 8450476]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3078":"<p><b>Title</b> Disopyramide / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Disopyramide. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of disopyramide if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Several reports describe decreases in serum disopyramide concentrations ranging from 30% to 75% in patients following the initiation of phenytoin therapy.<sup>1,2,3,4</sup> These pharmacokinetic changes occurred within approximately 1 week of initiation of combination therapy. Evidence of reduced disopyramide efficacy was noted in some cases (e.g., increased frequency of PVCs). The mechanism of this interaction is uncertain but is likely related to the ability of phenytoin to induce CYP3A4 enzymes of which disopyramide is a substrate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aitio ML and Vuorenmaa T, “Enhanced Metabolism and Diminished Efficacy of Disopyramide by Enzyme Induction,” <i>Br J Clin Pharmacol</i>, 1980, 9:149-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7356902\">[PubMed 7356902]</a></p>\n<p>2. Aitio ML, Mansury L, Tala E, et al, “The Effect of Enzyme Induction on the Metabolism of Disopyramide in Man,” <i>Br J Clin Pharmacol</i>, 1981, 279-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7213529\">[PubMed 7213529]</a></p>\n<p>3. Kessler JM, Keys PW, and Stafford RW, “Disopyramide and Phenytoin Interaction,” <i>Clin Pharm</i>, 1982, 1:263-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7185523\">[PubMed 7185523]</a></p>\n<p>4. Nightingale J and Nappi JM, “Effect of Phenytoin on Serum Disopyramide Concentrations,” <i>Clin Pharm</i>, 1987, 6:46-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816106\">[PubMed 3816106]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3079":"<p><b>Title</b> Beta-Blockers / Disopyramide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disopyramide may enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution if coadministering disopyramide and a beta-blocker (especially if both are IV); monitor for evidence of severe bradycardia and/or worsening heart failure. Atropine administration may not be effective in reversing the bradycardia.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n</div> \n<p><b>Discussion</b> In 7 patients with prior myocardial infarction, administration of atenolol (7.5 mg IV) or disopyramide (150 mg bolus followed by 22.6 mg/hour infusion) each resulted in a 14% decrease in cardiac index, and concomitant administration of both drugs reduced cardiac index by 33%.<sup>1</sup> Case reports also describe severe bradycardia and cardiovascular collapse when disopyramide was combined with either practolol or metoprolol.<sup>2,3</sup> Atropine did not always prove effective in reversing braycardia.<sup>2,3</sup> In a pharmacokinetic study of 6 ischemic heart disease patients and 3 healthy volunteers, atenolol 50 mg twice daily decreased the clearance of disopyramide (150 mg bolus followed by 0.3 to 0.4 mg/kg/hour continuous infusion) by 20%.<sup>4</sup><br><br>In contrast, in a study of 16 healthy volunteers, administration of propranolol or disopyramide each decreased cardiac output, but the combination did not have additive or synergistic effects.<sup>5</sup> A few small studies suggest that the combination of disopyramide and a beta-blocker may be beneficial for the treatment of hypertrophic cardiomyopathy and various arrhythmias.<sup>6,7,8</sup><br><br>Although not fully investigated, the mechanism of this potential interaction is likely the result of additive negative inotropic and negative chrontropic effects of both beta blockers and disopyramide.<sup>9,10</sup> The mechanism by which atenolol may decrease disopyramide clearance is unknown. Caution should be employed when these agents are combined, particularly if administered IV or to patients with decreased ventricular performance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bonde J, Pedersen LE, Angelo HR, et al. Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease. <i>Eur J Clin Pharmacol</i>. 1986;30(2):161-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3709640\">[PubMed 3709640]</a></p>\n<p>2. Cumming AD, Robertson C. Interaction between disopyramide and practolol. <i>Br Med J</i>. 1979;2(6200):1264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=519408\">[PubMed 519408]</a></p>\n<p>3. Pernat A, Pohar B, Horvat M. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy. <i>J Electrocardiol</i>. 1997;30(4):341-344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9375912\">[PubMed 9375912]</a></p>\n<p>4. Bonde J, Bodtker S, Angelo HR, Svendsen TL, Kampmann JP. Atenolol inhibits the elimination of disopyramide. <i>Eur J Clin Pharmacol</i>. 1985;28(1):41-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3987784\">[PubMed 3987784]</a></p>\n<p>5. Cathcart-Rake WF, Coker JE, Atkins FL, et al. The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men. <i>Circulation</i>. 1980;61(5):938-945. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7363436\">[PubMed 7363436]</a></p>\n<p>6. Cokkinos DV, Salpeas D, Ioannou NE, Christoulas S. Combination of disopyramide and propranolol in hypertrophic cardiomyopathy. <i>Can J Cardiol</i>. 1989;5(1):33-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2920304\">[PubMed 2920304]</a></p>\n<p>7. Bobrov VA, Frolov AI, Mitchenko EI, Galichansky IV, Zinchenko YuV. Comparative analysis of electrophysiologic effect of metoprolol and disopyramide, acting alone or in combination in patients with supraventricular tachycardia and Wolff-Parkinson-White syndrome. <i>Rev Port Cardiol</i>. 1994;13(3):221-225. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8049089\">[PubMed 8049089]</a></p>\n<p>8. Friehling TD, Lipshutz H, Marinchak RA, Stohler JL, Kowey PR. Effectiveness of propranolol added to a type I antiarrhythmic agent for sustained ventricular tachycardia secondary to coronary artery disease. <i>Am J Cardiol</i>. 1990;65(20):1328-1333. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2343820\">[PubMed 2343820]</a></p>\n<p>9. <i>Norpace</i> (disopyramide) [prescribing information]. Chicago, IL: GD Searle LLC; September 2001.</p>\n<p>10. <i>Tenormin</i> (atenolol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3081":"<p><b>Title</b> Isoniazid / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disulfiram may enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased CNS-related toxicities (e.g., problems with ambulation, alertness, affect, or behavior) during concomitant use of disulfiram and isoniazid.</p> \n<p><b>Discussion</b> Case reports describe the development of a variety of undesirable CNS-related symptoms during concurrent use of disulfiram (500 mg/day) and isoniazid (600-1000 mg/day).<sup>1</sup> Symptoms included problems with ambulation, alertness, affect, and behavior. The patients were stable on isoniazid when disulfiram was added. Symptoms manifested within approximately 1 week of starting the disulfiram, and decreased/dissipated when the disulfiram dosage was reduced by 25% to 50%. In contrast, no such symptoms were described in a case report and small retrospective review of patients receiving concomitant treatment with disulfiram and isoniazid.<sup>2,3</sup> <br><br>The mechanism of this interaction has not been investigated. Disulfiram is expected to increase systemic concentrations of isoniazid via inhibition of its CYP2E1 mediated metabolism. Other suggested mechanisms have included: synergism/addition of drug-specific side effects; or blocking of 2 of the 3 major metabolic pathways for dopamine (betahydroxylase - disulfiram; monoamine oxidase - isoniazid) thus forcing more metabolism through the COMT pathway and causing an increase in the toxic methylated metabolite of dopamine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Whittington HG and Grey L, “Possible Interaction Between Disulfiram and Isoniazid,” <i>Am J Psychiatry</i>, 1969, 125:1725. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5770196\">[PubMed 5770196]</a></p>\n<p>2. Rothstein E, “Rifampin and Disulfiram,” <i>JAMA</i>, 1972, 219:1216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5066886\">[PubMed 5066886]</a></p>\n<p>3. Burman WJ, Terra M, Breese P, et al, “Lack of Toxicity From Concomitant Directly Observed Disulfiram and Isoniazid-Containing Therapy for Active Tuberculosis,” <i>Int J Tuberc Lung Dis</i>, 2002, 6(9):839-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12234141\">[PubMed 12234141]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3083":"<p><b>Title</b> Phenytoin / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> If possible, avoid concomitant use of disulfiram and phenytoin. Monitor for increased serum concentrations/toxic effects of phenytoin if disulfiram is initiated or the dose is increased. Reduced phenytoin dosage will likely be needed. Monitor for decreased serum concentrations/effects of phenytoin if disulfiram is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Case reports demonstrate increases in serum phenytoin concentrations of at least 500% occurring over the course of several days following the initiation of disulfiram, with signs of toxicity occurring in some.<sup>1,2</sup> Notable changes started to occur within a few hours of initiating disulfiram, and lasted for several days (up to 3 weeks) following discontinuation of the disulfiram. Other similar reports are available.<sup>3,4,5</sup> An additonal case report describes a seizure episode occurring shortly after discontinuation of disulfiram in a patient who had previously been taking both phenytoin and disulfiram.<sup>6</sup><br><br>The mechanism of this interaction is unclear. Several studies have reported evidence of decreased phenytoin metabolism/clearance and increased elimination half-life with concurrent disulfiram.<sup>2,3,4</sup> Considering the primary role of CYP2C9 in phenytoin metabolism, disulfiram-mediated inhibition of CYP2C9 has been suggested as a possible mechanism. However, concurrent use of disulfiram with the model CYP2C9 substrate tolbutamide was not associated with any significant changes in tolbutamide half-life or clearance in a study of healthy volunteers,<sup>3</sup> and another study also concluded that single-dose disulfiram had no significant effect on CYP2C9 activity (measured as tolbutamide metabolic ratio) in vivo.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Olesen OV, “Disulfiram (Antabuse) as Inhibitor of Phenytoin Metabolism,” <i>Acta Pharmacol et Toxicol</i>, 1966, 24:317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6013115\">[PubMed 6013115]</a></p>\n<p>2. Olesen OV, “The Influence of Disulfiram and Calcium Carbamide on the Serum Diphenylhydantoin Excretion of HPPH in the Urine,” <i>Arch Neurol</i>, 1967, 16:642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6026073\">[PubMed 6026073]</a></p>\n<p>3. Svendesen TL, Kristensen MB, Hansen JM, et al, “The Influence of Disulfiram on the Half-Life and Metabolic Clearance Rate of Diphenylhydantoin and Tolbutamide in Man,” <i>Eur J Clin Pharmacol</i>, 1976, 9:439-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=971708\">[PubMed 971708]</a></p>\n<p>4. Taylor JW, Alexander B, and Lyon LW, “Mathematical Analysis of a Phenytoin-Disulfiram Interaction,” <i>Am J Hosp Pharm</i>, 1981, 38:93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7211876\">[PubMed 7211876]</a></p>\n<p>5. Brown CG, Kaminsky MJ, Feroli ER Jr, et al, “Delirium with Phenytoin and Disulfiram Administration,” <i>Ann Emerg Med</i>, 1983, 12(5):310-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6625283\">[PubMed 6625283]</a></p>\n<p>6. Birkett DJ, Graham GG, Chinwah PM, et al, “Multiple Drug Interactions with Phenytoin,” <i>Med J Aust</i>, 1977, 2(14):467-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=600148\">[PubMed 600148]</a></p>\n<p>7. Kharasch ED, Hankins DC, Jubert C, et al, “Lack of Single-Dose Disulfiram Effects on Cytochrome P-450 2C9, 2C19, 2D6, and 3A4 Activities: Evidence for Specificity Toward P-450 2E1,” <i>Drug Metab Dispos</i>, 1999, 27(6):717-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348802\">[PubMed 10348802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3084":"<p><b>Title</b> Theophylline Derivatives / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of theophylline derivatives if disulfiram is initiated/dose increased, or decreased effects if disulfiram is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of theophylline (5 mg/kg IV) was reduced by approximately 32% in 10 patients when administered following a 1-week course of disulfiram (500 mg/day).<sup>1</sup> Another 10 patients taking 250 mg of disulfiram daily showed a 21% decrease in theophylline clearance. The mechanism of this interaction is unknown, but may related to a disulfiram-related inhibition of CYP isoenzymes responsible for theophylline metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Loi CM, Day JD, Jue SG, et al, “Dose-Dependent Inhibition of Theophylline Metabolism by Disulfiram in Recovering Alcoholics,” <i>Clin Pharmacol Ther</i>, 1989, 45:476-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2721103\">[PubMed 2721103]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3085":"<p><b>Title</b> Disulfiram / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Disulfiram. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for toxic CNS effects if disulfiram and a monoamine oxidase inhibitor (MAOI) are concomitantly used. In general, furazolidone, linezolid, tedizolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. Disulfiram-stable patient developed acute delirium (disorientation, incoherence, visual hallucinations) within 2 days of initiating tranylcypromine.<sup>1</sup> The patient was also taking lithium. Prior to tranylcypromine, the patient was receiving moclobemide (a selective MAO inhibitor) without incident. The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Blansjaar BA and Egberts TC, “Delirium in a Patient Treated With Disulfiram and Tranylcypromine,” <i>Am J Psychiatry</i>, 1995, 152:296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7840370\">[PubMed 7840370]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3086":"<p><b>Title</b> Vitamin K Antagonists / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of vitamin K antagonists (eg, increased PT/INR, bleeding) if disulfiram is initiated or dose increased, or decreased effects if disulfiram is discontinued or dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, disulfiram (500 mg or 250 mg once daily for 4 days) increased the warfarin (1.5 mg/kg single oral dose) AUC 27%, and increased the mean prothrombin time (PT) 60%.<sup>1</sup> Similar changes in warfarin AUC and PT were seen when warfarin and disulfiram were coadministered for 21 days.<sup>1</sup> In another pharmacokinetic study of 7 healthy volunteers, disulfiram (250 mg once daily for 4 days) increased the PT 67% after administration of S-warfarin (0.75 mg/kg single oral dose).<sup>2</sup> Disulfiram had no effect on S-warfarin AUC or PT or on R-warfarin AUC after administration of R-warfarin (1.5 mg/kg single oral dose).<sup>2</sup> In support of these studies, 2 case reports describe patients on warfarin therapy who experienced a potentiation of warfarin effects upon the addition of disulfiram.<sup>3,4</sup><br><br>The mechanism of this potential interaction is likely related to the ability of disulfiram to weakly inhibit CYP2C9 or CYP1A2,<sup>5,6</sup> enzymes responsible for the metabolism of warfarin.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. O’Reilly RA. Interaction of sodium warfarin and disulfiram (antabuse) in man. <i>Ann Intern Med</i>. 1973;78(1):73-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4682311\">[PubMed 4682311]</a></p>\n<p>2. O’Reilly RA. Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. <i>Clin Pharmacol Ther</i>. 1981;29(3):332-336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7471603\">[PubMed 7471603]</a></p>\n<p>3. Rothstein E. Warfarin effect enhanced by disulfiram. <i>JAMA</i>. 1968;206(7):1574-1575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5695959\">[PubMed 5695959]</a></p>\n<p>4. Rothstein E. Warfarin effect enhanced by disulfiram (antabuse). <i>JAMA</i>. 1972;221(9):1052-1053. [PMID 5068297]</p>\n<p>5. Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. <i>Clin Pharmacol Ther</i>. 1989;45(5):476-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2721103\">[PubMed 2721103]</a></p>\n<p>6. Kharasch ED, Hankins DC, Jubert C, Thummel KE, Taraday JK. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. <i>Drug Metab Dispos</i>. 1999;27(6):717-723. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348802\">[PubMed 10348802]</a></p>\n<p>7. Coumadin (warfarin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3088":"<p><b>Title</b> Phenytoin / DOPamine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This possible interaction is only expected with intravenous administration of phenytoin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DOPamine may enhance the hypotensive effect of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased blood pressure in patients receiving intravenous phenytoin. Hemodynamically unstable patients, including those requiring dopamine to maintain adequate blood pressure, are at elevated risk.</p> \n<p><b>Discussion</b> Five case reports document significant and rapid reductions in blood pressure (previously maintained via a dopamine infusion) following the initiation of phenytoin infusion for seizure control.<sup>1</sup> One patient died from cardiopulmonary arrest. Another patient (receiving dopamine and dobutamine) did not experience any blood pressure change when a phenytoin infusion was initiated.<sup>2</sup> <br><br>The mechanism of this possible interaction is unknown. Hypotension is a known possible adverse effect of intravenous phenytoin administration, particularly in hemodynamically unstable patients, so the contribution of dopamine in producing this effect is questionable.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bivins BA, Rapp RP, Griffin WO Jr, et al, “Dopamine-Phenytoin Interaction. A Cause of Hypotension in the Critically Ill,” <i>Arch Surg</i>, 1978, 113(3):245-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=637689\">[PubMed 637689]</a></p>\n<p>2. Torres E, Garcia B, Sosa P, et al, “No Interaction Between Dopamine and Phenytoin,” <i>Ann Pharmacother</i>, 1995, 29:1300-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8672843\">[PubMed 8672843]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3089":"<p><b>Title</b> Calcium Channel Blockers / Alpha1-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased risk of hypotension during concomitant use of an alpha<sub>1</sub>-blocker and a calcium channel blocker. The risk associated with ophthalmic administration is probably less than with systemic administration.</p>\n<div>\n <p><b>Alpha1-Blockers Interacting Members</b> Alfuzosin, Doxazosin*, Indoramin, Moxisylyte, Naftopidil, Nicergoline, Phenoxybenzamine, Phentolamine, Prazosin*, Silodosin, Tamsulosin, Terazosin*</p>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The reduction in blood pressure of 12 healthy volunteers was greater during concomitant use (10 days) of doxazosin and nifedipine than with either drug alone.<sup>1</sup> Several other studies in both healthy volunteers and patients with hypertension have reported similar findings.<sup>2,3,4,5,6</sup><br><br>It is unclear whether this reported interaction is simply a result of additive blood pressure-lowering effects from the specific drugs involved, or if additional mechanism(s) is/are involved. Of note, several studies have found evidence that calcium channel blockers do exert some effects on alpha-1 receptors,<sup>7,8,9,10</sup> raising the possibility that a mechanism beyond simple additive blood pressure-lowering effects may be involved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Donnelly R, Elliott HL, Meredith PA, et al, “The Pharmacodynamics and Pharmacokinetics of the Combination of Nifedipine and Doxazosin,” Eur J Clin Pharmacol, 1993, 44:279-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8491245\">[PubMed 8491245]</a></p>\n<p>2. Ajayi AA, Raji MA, “Acute Cardiovascular Effects of the Concurrent Administration of Enalapril, Prazosin or Amlodipine in Healthy Nigerians,” <i>Int J Cardiol</i>, 1994, 44(1):79-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8021054\">[PubMed 8021054]</a></p>\n<p>3. Donnelly R, Elliott HL, Meredith PA, et al, “Combination of Nifedipine and Doxazosin in Essential Hypertension,” <i>J Cardiovasc Pharmacol</i>, 1992, 19(4):479-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1380588\">[PubMed 1380588]</a></p>\n<p>4. Kiss I, Farsang C, “Nifedipine-Prazosin Interaction in Patients with Essential Hypertension,” <i>Cardiovasc Drugs Ther</i>, 1989, 3(3):413-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2487537\">[PubMed 2487537]</a></p>\n<p>5. Elliott HL, Meredith PA, Campbell L, et al, “The Combination of Prazosin and Verapamil in the Treatment of Essential Hypertension,” <i>Clin Pharmacol Ther</i>, 1988, 43(5):554-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3284690\">[PubMed 3284690]</a></p>\n<p>6. Pasanisi F, Elliott HL, Meredith PA, et al, “Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects,” <i>Clin Pharmacol Ther</i>, 1984, 36(6):716-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6499353\">[PubMed 6499353]</a></p>\n<p>7. Bhalla RC, Sharma RV, “Competitive Interaction of Amiloride and Verapamil with alpha 1-adrenoceptors in vascular smooth muscle,” <i>J Cardiovasc Pharmacol</i>, 1986, 8(5):927-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2429092\">[PubMed 2429092]</a></p>\n<p>8. Muller A, Noack E, “Additive Competitive Interaction of Verapamil and Quinidine at Alpha-Adrenergic Receptors of Isolated Cardiac Guinea Pig Myocytes and Human Platelets,” <i>Life Sci</i>, 1988, 42(6):667-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2828798\">[PubMed 2828798]</a></p>\n<p>9. Nishimura J, Kanaide H, Nakamura M, “Binding of [3H]Prazosin to Porcine Aortic Membranes: Interaction of Calcium Antagonists with Vascular Alpha-1 Adrenoceptors,” <i>J Pharmacol Exp Ther</i>, 1986, 236(3):789-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3005556\">[PubMed 3005556]</a></p>\n<p>10. Reid JL, Pasanisi F, Meredith PA, et al, “Clinical Pharmacological Studies on the Interaction Between Alpha-Adrenoceptors and Calcium Antagonists,” <i>J Cardiovasc Pharmacol</i>, 1985, 7 Suppl 6:S206-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2414590\">[PubMed 2414590]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3091":"<p><b>Title</b> Methotrexate / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tetracyclines may increase the serum concentration of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for toxic effects of methotrexate if a tetracycline derivative is initiated or the dose is increased. This likely not a problem when using antirheumatic doses of methotrexate.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline*, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. Methotrexate (18 g IV for osteosarcoma treatment) clearance was reduced by 65% in a patient after initiating doxycycline (100 mg every 12 hours).<sup>1</sup> Gastrointestinal and hematologic toxicity accompanied the reduced clearance, and required drug discontinuation and leucovorin treatment. The patient had previously receiving several cycles of methotrexate without incident. The effect of doxycycline on lower doses of methotrexate is unknown. The mechanism of this interaction in unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tortajada-Ituren JJ, Ordovas-Baines JP, Llopis-Salvia P, et al, “High-Dose Methotrexate-Doxycycline Interaction,” <i>Ann Pharmacother</i>, 1999, 33:804-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10466909\">[PubMed 10466909]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3092":"<p><b>Title</b> Doxycycline / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Doxycycline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of doxycycline if used concurrently with phenytoin. Consideration might be given to increasing the dose of doxycycline at the initiation of phenytoin, or use of another tetracycline derivative may be considered to avoid this interaction.</p> \n<p><b>Discussion</b> A comparison of doxycycline half-life in 16 patients on long-term carbamazepine and/or phenytoin therapy revealed a 44-52% shorter half-life compared to controls (mean half-life = 15.1 hours; n=9).<sup>1</sup> For the patients taking phenytoin specifically, the mean doxycycline half-life was 7.2 hours (n=7), and for those taking both carbamazepine and phenytoin, the mean doxycycline half-life was 7.4 hours (n=4). Duration of carbamazepine and/or phenytoin therapy prior to this study was between 4 months and 10 years.<br><br>The suspected mechanism of this potential interaction is induction of doxycycline metabolism or excretion by phenytoin. The specific enzyme(s) and/or transporter(s) involved is uncertain, as most inducers like phenytoin are capable of inducing several metabolic enzymes and transport proteins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Penttila O, Neuvonen PH, Aho K, et al, “Interaction Between Doxycycline and Some Antiepileptic Drugs,” <i>Br Med J</i>, 1974, 2:470-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4600204\">[PubMed 4600204]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3093":"<p><b>Title</b> Doxycycline / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may decrease the serum concentration of Doxycycline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of doxycycline if used concurrently with a barbiturate. Use of another antimicrobial might be considered to avoid this interaction, or increasing the dose of doxycycline at the initiation of barbiturate therapy may be considered.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A comparison of doxycycline half-life in 5 patients on long-term (5 weeks to 30 years) barbiturate therapy revealed an mean 50% shorter half-life compared to 5 controls (mean half-life = 15.3 hours).<sup>1</sup> Additionally, administration of phenobarbital for 3 days to the control subjects was associated with a 27% reduction in doxycycline half-life. Animal data showing that phenobarbital treatment can increase the rate of doxycycline metabolism (to N-monomethyldoxycycline) supports this observed interaction.<sup>2</sup><br><br>The suspected mechanism of this potential interaction is induction of doxycycline metabolism or excretion by the barbiturates. The specific enzyme(s) and/or transporter(s) involved is uncertain, as most inducers like phenobarbital are capable of inducing several metabolic enzymes and transport proteins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Neuvonen PJ and Penttila O, “Interaction Between Doxycycline and Barbiturates,” <i>Br Med J</i>, 1974, 1:535-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4817187\">[PubMed 4817187]</a></p>\n<p>2. Bocker R, “Analysis and Quantitation of a Metabolite of Doxycycline in Mice, Rats, and Humans by High-Performance Liquid Chromatography,” <i>J Chromatogr</i>, 1983, 274:255-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6874826\">[PubMed 6874826]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3094":"<p><b>Title</b> Vitamin K Antagonists / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of coumarin derivatives if a tetracycline derivative is initiated/dose increased, or decreased effects if a tetracycline derivative is discontinued/dose decreased.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline*, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Though usually of no consequence, a number of reports describe increased hypoprothrombinemic effects of warfarin following the initiation of doxycycline<sup>1,2</sup> or tetracycline,<sup>3</sup> with evidence of bleeding occurring in some. In one report, changes in warfarin response seemed to be related to the dosage of tetracycline.<sup>3</sup> The mechanism of these interactions is unknown. Postulated mechanisms include: a tetracycline-induced reduction in prothrombin activity;<sup>4,5</sup> or a reduction in GI flora essential for vitamin K production, which is subsequently used to produce various clotting factors (seemingly of limited impact).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Westfall LK, Mintzer DL, and Wiser TH, “Potentiation of Warfarin by Tetracycline,” <i>Am J Hosp Pharm</i>, 1980, 37:1620-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7446537\">[PubMed 7446537]</a></p>\n<p>2. Caraco Y and Rubinow A, “Enhanced Anticoagulant Effect of Coumarin Derivatives Induced by Doxycycline Coadministration,” <i>Ann Pharmacother</i>, 1992, 26:1084-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1421670\">[PubMed 1421670]</a></p>\n<p>3. Danos EA, “Apparent Potentiation of Warfarin Activity by Tetracycline,” <i>Clin Pharm</i>, 1992, 11:806-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1521405\">[PubMed 1521405]</a></p>\n<p>4. Searcy RL, Simms NM, Foreman JA, et al, “Evaluation of the Blood-Clotting Mechanism in Tetracycline-Treated Patients,” <i>Antimicrob Agents Chemother</i>, 1965, 179-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14287926\">[PubMed 14287926]</a></p>\n<p>5. Rios JF, “Haemorrhagic Diathesis Induced by Antimicrobials,” <i>JAMA</i>, 1968, 205:142.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3095":"<p><b>Title</b> Alpha-/Beta-Agonists (Direct-Acting) / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If used, monitor for evidence of increased pressor effects (eg, increased blood pressure, chest pain, headache). Additionally, reductions in initial dosages of the direct acting alpha-/beta-agonist should be considered.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists (Direct-Acting) Interacting Members</b> DOPamine, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Isometheptene, Levonordefrin, Metaraminol, Norepinephrine*</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine*, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline*, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The blood pressure elevating effects of intravenous epinephrine, norepinephrine, and phenylephrine were markedly increased (2- to 9-fold) in several reports when administered to patients receiving tricyclic antidepressants.<sup>1,2,3,4,5</sup> Sympathomimetic-related side effects (eg, headache, chest pain) were also reported in 3 patients receiving various tricyclic antidepressants when concomitantly administered a local anesthetic combined with norepinephrine (1:25,000) for a dental procedure.<sup>6</sup> Smaller increases in norepinephrine sensitivity were reported with doxepin.<sup>7</sup> In contrast, one study reported only a small, but insignificant, increase in the blood pressure elevating effects of intravenous epinephrine when combined with imipramine,<sup>4</sup> and other reports describe a decreased pressor response to intravenous phenylephrine when combined with amitriptyline.<sup>5,8</sup><br><br>Prescribing information for imipramine, as well as several direct acting alpha-/beta-agonists, warns of the potential for the potentiation of pressor effects when these agents are combined.<sup>9,10,11,12</sup> Label warnings are stronger, advising against concomitant use, for epinephrine products not intended for use in a life threatening situation (eg, for procedural use in combination with local anesthetics, inhaled).<sup>13,14,15,16</sup><br><br>The proposed mechanism of this interaction is that tricyclic antidepressants block norepinephrine uptake into adrenergic neurons, thus leaving higher concentrations in the synapse. The exogenous administration of a direct-acting alpha-/beta-agonist leads to overstimulation of the adrenergic receptors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Svedmyr N. The influence of a tricyclic antidepressive agent (protriptyline) on some circulatory effects of noradrenaline and adrenaline in man. <i>Life Sci</i>. 1968;7(1):77-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5636628\">[PubMed 5636628]</a></p>\n<p>2. Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. <i>Br Med J</i>. 1973;1(5849):311-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>3. Mitchell JR, Cavanaugh JH, Arias L, Oates JA. Guanethidine and related agents. III. Antagonism by drugs which inhibit the norepinephrine pump in man. <i>J Clin Invest</i>. 1970;49(8):1596-1604. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5431666\">[PubMed 5431666]</a></p>\n<p>4. Gershon S, Holmberg G, Mattsson E, Mattsson N, Marshall A. Imipramine hydrochloride. Its effects on clinical, autonomic and psychological functions. <i>Arch Gen Psychiatry</i>. 1962;6(1):96-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13898068\">[PubMed 13898068]</a></p>\n<p>5. Ghose K. Assessment of peripheral adrenergic activity and its interactions with drugs in man. <i>Eur J Clin Pharmacol</i>. 1980;17(4):233-238. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6105078\">[PubMed 6105078]</a></p>\n<p>6. Boakes AJ, Laurence DR, Lovel KW, O'Neill R, Verrill PJ. Adverse reactions to local anaesthetic/vasoconstrictor preparations. A study of the cardiovascular responses to Xylestin and Hostacain-with-Adrenaline. <i>Br Dent J</i> 1972;133(4):137-140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4507157\">[PubMed 4507157]</a></p>\n<p>7. Oates JA, Fann WE, Cavanaugh JH. Effect of doxepin on the norepinephrine pump. A preliminary report. <i>Psychosomatics</i>. 1969;10(3):12-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5822695\">[PubMed 5822695]</a></p>\n<p>8. Ghose K, Rama Rao VA, Bailey J, Coppen A. Antidepressant activity and pharmacological interactions of ciclazindol. <i>Psychopharmacology (Berl)</i>. 1978;57(1):109-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=96461\">[PubMed 96461]</a></p>\n<p>9. Imipramine [prescribing information]. Fairfield, NJ: Excellium Pharmaceutical Inc; October 2012.</p>\n<p>10. <i>Adrenaclick</i> (epinephrine) [prescribing information]. Horsham, PA: Amedra Pharmaceuticals LLC; April 2014.</p>\n<p>11. Dopamine hydrochloride [prescribing information]. Lake Forest, IL: Hospira Inc; May 2014.</p>\n<p>12. Norepinephrine bitartrate [prescribing information]. Irvine, CA: Teva Parenteral Medicines Inc; August 2009.</p>\n<p>13. Bupivacaine hydrochloride and epinephrine [prescribing information]. Lake Forest, IL: Hospira Inc; December 2009.</p>\n<p>14. <i>Xylocaine</i> (lidocaine hydrochloride and epinephrine) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; February 2010.</p>\n<p>15. <i>Primatene</i> (epinephrine) [prescribing information]. Madison, NJ: Wyeth Consumer Healthcare; August 2001.</p>\n<p>16. <i>Scandonest</i> (mepivacaine hydrochloride and adrenaline) [summary of product characteristics]. Saint-Maur-des-Fosses, France: Septodont; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3096":"<p><b>Title</b> Alpha-/Beta-Agonists (Indirect-Acting) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of indirect-acting alpha/beta agonists and monoamine oxidase inhibitors should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised, particularly monitoring for increased blood pressure. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists (Indirect-Acting) Interacting Members</b> Amezinium, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), Pseudoephedrine*</p>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Methylene Blue, Moclobemide*, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine*<br><b>Exceptions</b> Linezolid, Tedizolid</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Monoamine oxidase inhibitors (nonselective) cause an accumulation of norepinephrine within adrenergic neurons. Of particular importance are the neurons in the sympathetic system that innervate arterial blood vessels. Under such circumstances, the administration of an indirect-acting alpha-/beta-agonist (or any other indirect-acting sympathomimetic) will cause the release of the stored, excess norepinephrine, and a subsequent exaggerated constriction of blood vessels - thus an exaggerated increase in blood pressure.<sup>1,2,3,4,5</sup> The hypertensive reactions can occur within minutes of sympathomimetic administration. Fatalities have occurred. The effect of selective MAOIs on alpha-/beta-agonist toxicity is less likely than with nonselective products; however, one report describes a three- to fourfold increase in the pressor effects of ephedrine in subjects receiving moclobemide.<sup>6,7</sup> Linezolid is reported to cause minimal (but statistically significant) changes in serum concentrations of the alpha-/beta-agonists, with small increases in blood pressure noted in most subjects.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jenkins LC and Graves HB, “Potential Hazards of Psychoactive Drugs in Association With Anaesthesia,” <i>Can Anaesth Soc J</i>, 1965, 12:121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14311657\">[PubMed 14311657]</a></p>\n<p>2. Elis J, Laurence DR, Mattie H, et al, “Modification by Monoamine Oxidase Inhibitors of the Effects of Some Sympathomimetics on Blood Pressure,” <i>Br Med J</i>, 1967, 2:75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6020852\">[PubMed 6020852]</a></p>\n<p>3. Low-Beer GA and Tidmarsh D, “Collapse After Parstelin,” <i>Br Med J</i>, 1963, 2:683. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14044878\">[PubMed 14044878]</a></p>\n<p>4. Wright SP, “Hazards With Monoamine Oxidase Inhibitors: A Persistent Problem,” <i>Lancet</i>, 1978, i:284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=74715\">[PubMed 74715]</a></p>\n<p>5. Harrison WM, McGrath PJ, Stewart JW, et al, “MAOIs and Hypertensive Crises: The Role of OTC Drugs,” <i>J Clin Psychiatry</i>, 1989, 50:64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2464583\">[PubMed 2464583]</a></p>\n<p>6. Dingemanse J, “An Update of Recent Moclobemide Interaction Data,” <i>Int Clin Psychopharmacol</i>, 1993, 7:167-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8468439\">[PubMed 8468439]</a></p>\n<p>7. Dingemanse J, Guentert T, Gieschke R, et al, “Modification of the Cardiovascular Effects of Ephedrine by the Reversible Monoamine Oxidase A-Inhibitor Moclobemide,” <i>J Cardiovasc Pharmacol</i>, 1996, 28:856-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8961085\">[PubMed 8961085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3098":"<p><b>Title</b> Alpha-/Beta-Agonists (Direct-Acting) / Beta-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increases in pressor effects of alpha-/beta-agonists if used in patients receiving beta-blocker therapy (including ophthalmic products). Beta1-selective (i.e., “cardioselective”) agents may confer a more limited risk if used in low enough doses to allow them to retain their selectivity. The amount of epinephrine used in dental procedures as part of local anesthetic administration is not likely to be of clinical concern. Infiltrating larger volumes of local anesthetics for other surgical procedures (e.g., more than 0.06mg epinephrine) may cause clinically-relevant problems. Patients with allergies that require carrying and periodically using subcutaneous epinephrine (e.g., bee sting kits) should probably avoid the use of beta blockers.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists (Direct-Acting) Interacting Members</b> DOPamine, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Isometheptene, Levonordefrin, Metaraminol, Norepinephrine</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Blood pressure was increased by 20-40 mmHg, and heart rate decreased 23-36 beats/minute in 9 individuals following administration of 0.4mg epinephrine SubQ when pretreated with propranolol 40mg.<sup>1</sup> Similar responses were noted when 6 propranolol-treated patients (20-80 mg/day) received face or eyelid infiltration (8-40mL) of a solution containing 1:100,000 or 1:200,000 epinephrine (and lidocaine) for a plastic surgery procedure.<sup>2</sup> Similar responses associated with these two agents are reported elsewhere.<sup>3,4,5,6,7,8</sup> One of the reports supports the theory that cardioselective beta-blockers (e.g., metoprolol) would exhibit a lower interaction potential (as long as cardioselective doses are used).<sup>4</sup> It is important to note that “cardioselectivity” is only relative, and that at higher doses, relatively beta1-selective agents may lose their selectivity and have clinically significant beta2-blocking effects. Phenylephrine, on the other hand, does not appear to be affected by concomitant beta-blocker therapy, whether given intranasally or IV.<sup>9,10</sup> The effects of epinephrine serve to constrict peripheral blood vessels (alpha/constrictive effects greater than beta<sub>2</sub>/dilating effects in the periphery), and increase the heart rate (beta<sub>1</sub>). Nonselective beta-blocker therapy results in unopposed alpha effects, and significant vasoconstriction. A subsequent decrease in heart rate occurs due to increased vagal tone (reflex).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Varma DR, Sharma KK, and Arora RC, “Response to Adrenaline and Propranolol in Hyperthyroidism,” <i>Lancet</i>, 1976, 1:260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55579\">[PubMed 55579]</a></p>\n<p>2. Foster CA and Aston SJ, “Propranolol-Epinephrine Interaction: A Potential Disaster,” <i>Plast Reconstr Surg</i>, 1983, 72:74-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6867180\">[PubMed 6867180]</a></p>\n<p>3. Kram J, Bourne HR, Melmon KL, et al, “Propranolol,” <i>Ann Intern Med</i>, 1974, 80:282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9811811\">[PubMed 9811811]</a></p>\n<p>4. van Herwaarden CL, “Effects of Adrenaline During Treatment With Propranolol and Metoprolol,” <i>Br Med J</i>, 1977, 2:1029. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=322808\">[PubMed 322808]</a></p>\n<p>5. Berchtold P and Bessman AN, “Propranolol,” <i>Ann Intern Med</i>, 1974, 80:119.</p>\n<p>6. Hansbrough JF and Near A, “Propranolol-Epinepherine Antagonism With Hypertension and Stroke,” <i>Ann Intern Med</i>, 1980, 92:717.</p>\n<p>7. Gandy W, “Severe Epinephrine-Propranolol Interaction,” <i>Ann Emerg Med</i>, 1989, 18:98-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910169\">[PubMed 2910169]</a></p>\n<p>8. Centeno RF, Yu YL, “The Propanolol-Epinephrine Interaction Revisited: A Serious and Potentially Catastrophic Adverse Drug Interaction in Facial Plastic Surgery,” <i>Plast Reconstr Surg</i>, 2003, 111(2):944-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12560730\">[PubMed 12560730]</a></p>\n<p>9. Myers MG and Iazetta JJ, “Intranasally Administered Phenylephrine and Blood Pressure,” <i>Can Med Ass J</i>, 1982, 127:365-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7104913\">[PubMed 7104913]</a></p>\n<p>10. Myers MG, “Beta-Adrenoceptor Antagonism and Pressor Response to Phenylephrine,” <i>Clin Pharmacol Ther</i>, 1984, 36:57-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734050\">[PubMed 6734050]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3099":"<p><b>Title</b> Nitroglycerin / Ergot Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of ergot derivatives in patients receiving nitroglycerin for angina (or in any angina patient). If concomitant treatment cannot be avoided, monitor for decreased effects of nitroglycerin and increased adverse effects of the ergot derivative (e.g., ergotism).</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Cabergoline, Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine*, Methylergonovine, Pergolide<br><b>Exception</b> Nicergoline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Ergot alkaloids are known precipitants of angina and would be expected to oppose the antianginal effects of nitroglycerin.<sup>1</sup> Additionally, nitroglycerin increases the bioavailability of dihydroergotamine and could thereby increase the risk of adverse effects (e.g., ergotism).<sup>1,2</sup> It is unknown whether the bioavailability of ergot derivatives other than dihydroergotamine would be similarly affected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nitromist (nitroglycerin). Cranford, NJ: Akrimax Pharmaceuticals, LLC, November 2010.</p>\n<p>2. Bobik A, Jennings G, Skews H, et al, “Low Oral Bioavailability of Dihydroergotamine and First-Pass Extraction in Patients With Orthostatic Hypotension,” <i>Clin Pharmacol Ther</i>, 1981, 30:673-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794970\">[PubMed 6794970]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}